AU2011338302A1 - Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof - Google Patents

Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof Download PDF

Info

Publication number
AU2011338302A1
AU2011338302A1 AU2011338302A AU2011338302A AU2011338302A1 AU 2011338302 A1 AU2011338302 A1 AU 2011338302A1 AU 2011338302 A AU2011338302 A AU 2011338302A AU 2011338302 A AU2011338302 A AU 2011338302A AU 2011338302 A1 AU2011338302 A1 AU 2011338302A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
cycloalkyl
haloalkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011338302A
Inventor
Alexander R. Hurd
Clarke B. Taylor
Peter L. Toogood
Chad A. Vanhuis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lycera Corp
Original Assignee
Lycera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lycera Corp filed Critical Lycera Corp
Publication of AU2011338302A1 publication Critical patent/AU2011338302A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

The invention provides cycloalkyl guanidine compounds that inhibit F

Description

WO 2012/078867 PCT/US2011/063943 CYCLOALKYL GUANIDINE F 1 Fo-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of and priority to United States Provisional Patent Application serial number 61/420,899, filed December 8, 2010, the contents of which are hereby incorporated by reference. FIELD OF THE INVENTION [0002] The invention provides inhibitors of FiFo-ATPases (e.g., mitochondrial FIFo 5 ATPases) and their therapeutic use. In particular, the invention provides cycloalkyl guanidine compounds that inhibit FiFo-ATPase, and methods of using cyclalkyl guanidine compounds as therapeutic agents to treat a number of medical conditions. BACKGROUND [0003] Multicellular organisms exert precise control over cell number. A balance between cell proliferation and cell death achieves this homeostasis. Cell death occurs in nearly every 10 type of vertebrate cell via necrosis or through a suicidal form of cell death, known as apoptosis. Apoptosis is triggered by a variety of extracellular and intracellular signals that engage a common, genetically programmed death mechanism. [0004] Multicellular organisms use apoptosis to instruct damaged or unnecessary cells to destroy themselves for the good of the organism. Control of the apoptotic process therefore is 15 very important to normal development, for example, fetal development of fingers and toes requires the controlled removal, by apoptosis, of excess interconnecting tissues, as does the formation of neural synapses within the brain. Similarly, controlled apoptosis is responsible for the sloughing off of the inner lining of the uterus (the endometrium) at the start of menstruation. While apoptosis plays an important role in tissue sculpting and normal cellular 20 maintenance, it is also a component of the primary defense against cells and invaders (e.g., viruses) which threaten the well being of the organism.
WO 2012/078867 PCT/US2011/063943 -2 [0005] Not surprisingly many diseases are associated with dysregulation of apoptotic cell death. Experimental models have established a cause-effect relationship between aberrant apoptotic regulation and the pathagenicity of various neoplastic, autoimmune and viral diseases. For instance, in the cell-mediated immune response, effector cells (e.g., cytotoxic T 5 lymphocytes "CTLs") destroy virus-infected cells by inducing the infected cells to undergo apoptosis. The organism subsequently relies on the apoptotic process to destroy the effector cells when they are no longer needed. Autoimmunity is normally prevented by the CTLs inducing apoptosis in each other and even in themselves. Defects in this process are associated with a variety of immune diseases such as lupus erythematosus and rheumatoid arthritis. 10 [0006] Multicellular organisms also use apoptosis to instruct cells with damaged nucleic acids (e.g., DNA) to destroy themselves prior to becoming cancerous. Some cancer-causing viruses overcome this safeguard by reprogramming infected (transformed) cells to abort the normal apoptotic process. For example, several human papilloma viruses (HPVs) have been implicated in causing cervical cancer by suppressing the apoptotic removal of transformed cells 15 by producing a protein (E6) which inactivates the p53 apoptosis promoter. Similarly, the Epstein-Barr virus (EBV), the causative agent of mononucleosis and Burkitt's lymphoma, reprograms infected cells to produce proteins that prevent normal apoptotic removal of the aberrant cells thus allowing the cancerous cells to proliferate and to spread throughout the organism. 20 [0007] Still other viruses destructively manipulate a cell's apoptotic machinery without directly resulting in the development of a cancer. For example, destruction of the immune system in individuals infected with the human immunodeficiency virus (HIV) is thought to progress through infected CD4' T cells (about 1 in 100,000) instructing uninfected sister cells to undergo apoptosis. 25 [0008] Some cancers that arise by non-viral means have also developed mechanisms to escape destruction by apoptosis. Melanoma cells, for instance, avoid apoptosis by inhibiting the expression of the gene encoding Apaf-1. Other cancer cells, especially lung and colon cancer cells, secrete high levels of soluble decoy molecules that inhibit the initiation of CTL mediated clearance of aberrant cells. Faulty regulation of the apoptotic machinery has also 30 been implicated in various degenerative conditions and vascular diseases.
WO 2012/078867 PCT/US2011/063943 -3 [0009] Controlled regulation of the apoptotic process and its cellular machinery is important to the survival of multicellular organisms. Typically, the biochemical changes that occur in a cell instructed to undergo apoptosis occur in an orderly procession. However, as shown above, flawed regulation of apoptosis can cause serious deleterious effects in the organism. 5 [0010] The need exists for improved compositions and methods for regulating the apoptotic processes in subjects afflicted with diseases and conditions characterized by faulty regulation of these processes (e.g., viral infections, hyperproliferative autoimmune disorders, chronic inflammatory conditions, and cancers). The present invention addresses this need and provides other related advantages. SUMMARY 10 [0011] The invention provides cycloalkyl guanidine compounds that inhibit FiFo-ATPase (e.g., mitochondrial FiFo-ATPase), and methods of using such compounds as therapeutic agents to treat a number of conditions. Accordingly, one aspect of the invention provides a family of compounds represented by Formula I: 0 (R')n "R 2 R2N N R 4 & R3 15 (I) including all stereoisomers, geometric isomers, and tautomers; or a pharmaceutically acceptable salt or solvate of any of the foregoing, wherein the variables are as defined in the detailed description. The foregoing compounds can be present in a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable 20 carrier. [0012] Another aspect of the invention provides a method of treating a subject suffering from a medical disorder. The method comprises administering to the subject a therapeutically effective amount of one or more cycloalkyl guanidine compounds described herein, e.g., a compound of Formula I. A large number of disorders can be treated using the cycloalkyl 25 guanidine compounds described herein. For example, the compounds described herein can be WO 2012/078867 PCT/US2011/063943 -4 used to treat an immune disorder or inflammatory disorder, such as rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, 5 scleroderma, ulcerative colitis, asthma, epidermal hyperplasia, and other medical disorders described herein. The compounds described herein can also be used to treat a cardiovascular disease, myeloma, lymphoma, cancer, or bacterial infection. [0013] Another aspect of the invention provides a method of inhibiting an FiFo-ATPase, for example, a mitochondrial FiFo-ATPase. The method comprises exposing the FiFo-ATPase to a 10 compound described herein, such as a compound of Formula I. DETAILED DESCRIPTION OF THE INVENTION [0014] The invention provides cycloalkyl guanidine compounds that inhibit FiFo-ATPase (e.g., mitochondrial FiFo-ATPase), pharmaceutical compositions comprising the cycloalkyl guanidine compounds, and methods of using the cycloalkyl guanidine compounds and pharmaceutical compositions in therapy. 15 [0015] Exemplary compositions and methods of the present invention are described in more detail in the following sections: II. Modulators of FiFo-ATPase Activity; III. Guanidine Compounds; IV. Therapeutic Applications of Guanidine Compounds, and V. Pharmaceutical Compositions, Formulations, and Exemplary Administration Routes and Dosing Considerations. Certain definitions are provided in section I. Aspects of the invention 20 described in one particular section are not to be limited to any particular section. [0016] The practice of the present invention employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as "Comprehensive 25 Organic Synthesis" (B.M. Trost & I. Fleming, eds., 1991-1992); "Molecular cloning: a laboratory manual" Second Edition (Sambrook et al., 1989); "Oligonucleotide synthesis" (M.J. Gait, ed., 1984); "Animal cell culture" (R.I. Freshney, ed., 1987); the series "Methods in enzymology" (Academic Press, Inc.); "Handbook of experimental immunology" (D.M. Weir & C.C. Blackwell, eds.); "Gene transfer vectors for mammalian cells" (J.M. Miller & M.P. Calos, 30 eds., 1987); "Current protocols in molecular biology" (F.M. Ausubel et al., eds., 1987, and WO 2012/078867 PCT/US2011/063943 -5 periodic updates); "PCR: the polymerase chain reaction" (Mullis et al., eds., 1994); and "Current protocols in immunology" (J.E. Coligan et al., eds., 1991), each of which is herein incorporated by reference in its entirety. I. Definitions 5 [0017] To facilitate an understanding of the present invention, a number of terms and phrases are defined below. [0018] As used herein, the term "guanidine" refers to a compound having the following core N A N ',N structure: I , including pharmaceutically acceptable salt forms. [0019] The term "alkyl" refers to a saturated straight or branched hydrocarbon, such as a 10 straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C 1
-C
12 alkyl,
C
1 -Cioalkyl, and C 1
-C
6 alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3 methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-i pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2 15 dimethyl-i-butyl, 3,3-dimethyl-i-butyl, 2-ethyl-i-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc. [0020] The term "haloalkyl" refers to an alkyl group that is substituted with at least one halogen. For example, -CH 2 F, -CHF 2 , -CF 3 , -CH 2
CF
3 , -CF 2
CF
3 , and the like. [0021] The term "cycloalkyl" refers to a monovalent saturated cyclic, bicyclic, or bridged 20 cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as "C 4
_
8 cycloalkyl," derived from a cycloalkane. Exemplary cycloalkyl groups include cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl. [0022] The term "cycloalkylene" refers to a divalent (i.e., diradical) saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, 25 referred to herein, e.g., as "C 4
_
8 cycloalkylene," derived from a cycloalkane. Unless specified otherwise, the cycloalkylene may be substituted at one or more ring positions with, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, WO 2012/078867 PCT/US2011/063943 -6 nitro, sulfhydryl, imino, amido, carboxylic acid, -C(O)alkyl, -CO 2 alkyl, carbonyl, carboxyl, alkylthio, sulfonyl, sulfonamido, sulfonamide, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, -CF 3 , -CN, or the like. In certain embodiments, the cycloalkylene group is substituted with 1, 2, or 3 substituents independently selected from the group consisting of 5 halogen, hydroxyl, alkoxyl, and amino. In certain other embodiments, the cycloalkylene group is not substituted, i.e., it is unsubstituted. Exemplary cycloalkylene groups include and . [0023] The term "aralkyl" refers to an alkyl group substituted with an aryl group. [0024] The term "heteroaralkyl" refers to an alkyl group substituted with a heteroaryl group. 10 [0025] The term "alkenyl" refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched group of 2-12, 2-10, or 2-6 carbon atoms, referred to herein as C 2 _C1 2 alkenyl, C 2 _Cioalkenyl, and C 2
_C
6 alkenyl, respectively. Exemplary alkenyl groups include, but are not limited to, vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4 15 (2-methyl-3-butene)-pentenyl, etc. [0026] The term "alkynyl" as used herein refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond, such as a straight or branched group of 2-12, 2-8, or 2-6 carbon atoms, referred to herein as C 2 -C1 2 alkynyl, C 2
_C
8 alkynyl, and C 2 C 6 alkynyl, respectively. Exemplary alkynyl groups include, but are not limited to, ethynyl, 20 propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2 pentynyl, and 4-butyl-2-hexynyl, etc. [0027] The term "aryl" is art-recognized and refers to a carbocyclic aromatic group. Representative aryl groups include phenyl, naphthyl, anthracenyl, and the like. Unless specified otherwise, the aromatic ring may be substituted at one or more ring positions with, for 25 example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, carboxylic acid, -C(O)alkyl, -CO 2 alkyl, carbonyl, carboxyl, alkylthio, sulfonyl, sulfonamido, sulfonamide, ketone, aldehyde, ester, heterocyclyl, heteroaryl,
-CF
3 , -CN, or the like. The term "aryl" also includes polycyclic ring systems having two or more carbocyclic rings in which two or more carbons are common to two adjoining rings (the WO 2012/078867 PCT/US2011/063943 -7 rings are "fused rings") wherein at least one of the rings is aromatic, and the other ring(s) may be, for example, cycloalkyl, cycloalkenyl, cycloalkynyl, and/or aryl. The term "haloaryl" refers to an aryl group that is substituted with at least one halogen. In certain embodiments, the aromatic group is not substituted, i.e., it is unsubstituted. 5 [0028] The terms "heterocyclyl" or "heterocyclic group" are art-recognized and refer to saturated, partially unsaturated, or aromatic 3- to 10-membered ring structures, alternatively 3 to 7-membered rings, whose ring structures include one to four heteroatoms, such as nitrogen, oxygen, and sulfur. Heterocycles may also be mono-, bi-, or other multi-cyclic ring systems. A heterocycle may be fused to one or more aryl, partially unsaturated, or saturated rings. 10 Heterocyclyl groups include, for example, biotinyl, chromenyl, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl, dithiazolyl, homopiperidinyl, imidazolidinyl, isoquinolyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, oxolanyl, oxazolidinyl, phenoxanthenyl, piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazolinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidin-2-onyl, pyrrolinyl, tetrahydrofuryl, tetrahydroisoquinolyl, tetrahydropyranyl, 15 tetrahydroquinolyl, thiazolidinyl, thiolanyl, thiomorpholinyl, thiopyranyl, xanthenyl, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like. Unless specified otherwise, the heterocyclic ring is optionally substituted at one or more positions with substituents such as alkanoyl, alkoxy, alkyl, alkenyl, alkynyl, amido, amidino, amino, aryl, arylalkyl, azido, carbamate, carbonate, carboxy, cyano, cycloalkyl, ester, ether, formyl, 20 halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, imino, ketone, nitro, phosphate, phosphonato, phosphinato, sulfate, sulfide, sulfonamido, sulfonyl and thiocarbonyl. In certain embodiments, the heterocyclcyl group is not substituted, i.e., it is unsubstituted. [0029] The term "heteroaryl" is art-recognized and refers to aromatic groups that include at least one ring heteroatom. In certain instances, a heteroaryl group contains 1, 2, 3, or 4 ring 25 heteroatoms. Representative examples of heteroaryl groups includes pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl and pyrimidinyl, and the like. Unless specified otherwise, the heteroaryl ring may be substituted at one or more ring positions with, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, 30 carboxylic acid, -C(O)alkyl, -CO 2 alkyl, carbonyl, carboxyl, alkylthio, sulfonyl, sulfonamido, sulfonamide, ketone, aldehyde, ester, heterocyclyl, aryl, -CF 3 , -CN, or the like. The term "heteroaryl" also includes polycyclic ring systems having two or more rings in which two or WO 2012/078867 PCT/US2011/063943 -8 more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is heteroaromatic, and the other ring(s) may be, for example, cycloalkyl, cycloalkenyl, cycloalkynyl, and/or aryl. [0030] The terms ortho, meta and para are art-recognized and refer to 1,2-, 1,3- and 1,4 5 disubstituted benzenes, respectively. For example, the names 1,2-dimethylbenzene and ortho dimethylbenzene are synonymous. [0031] The terms "amine" and "amino" are art-recognized and refer to both unsubstituted and substituted amines, e.g., a moiety that may be represented by the general formulas: R0 R50 - A54 + -_N - N-R53 R1 R52 50 51 52 53 10 wherein R , R , R and R each independently represent a hydrogen, an alkyl, an alkenyl, 61 50 51
-(CH
2 )m-R , or R and R , taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; m is zero or an integer in the range of 1 to 8, and A54 is an anion, such as Cl-, F-, Br, F, or OC(O)-C1-C 4 -alkyl. In certain 15 embodiments, only one of R 5 0 or R may be a carbonyl, e.g., R 0 , R and the nitrogen together do not form an imide. In other embodiments, R 5 0 and R 51 (and optionally R 52 ) each 61 independently represent a hydrogen, an alkyl, an alkenyl, or -(CH 2 )m-R [0032] The terms "alkoxyl" or "alkoxy" are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups 20 include methoxy, ethoxy, propyloxy, tert-butoxy and the like. An "ether" is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as may be represented by one of -0-alkyl, -0-alkenyl, 61 61 -0-alkynyl, -O-(CH 2 )m-R , where m and R are described above. [0033] The term "amide" or "amido" as used herein refers to a radical of the form 25 -RaC(O)N(Rb)-, -RaC(O)N(Rb)Rc-, -C(O)NRbRc, or -C(O)NH 2 , wherein Ra, Rb and Rc are each independently selected from alkoxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, and nitro. The amide can be attached to another group through the WO 2012/078867 PCT/US2011/063943 -9 carbon, the nitrogen, Rb, Rc, or Ra. The amide also may be cyclic, for example Rb and Rc, Ra and Rb, or Ra and Rc may be joined to form a 3- to 12-membered ring, such as a 3- to 10 membered ring or a 5- to 6-membered ring. The term "carboxamido" refers to the structure -C(O)NRbRc. 5 [0034] The term "sulfonamide" or "sulfonamido" as used herein refers to a radical having the structure -N(Rr)-S(O) 2 -Rs- or -S(O) 2 -N(Rr)Rs, where Rr, and Rs can be, for example, hydrogen, alkyl, aryl, cycloalkyl, and heterocyclyl. Exemplary sulfonamides include alkylsulfonamides (e.g., where Rs is alkyl), arylsulfonamides (e.g., where Rs is aryl), cycloalkyl sulfonamides (e.g., where Rs is cycloalkyl), and heterocyclyl sulfonamides (e.g., 10 where Rs is heterocyclyl), etc. [0035] The term "sulfonyl" as used herein refers to a radical having the structure RuSO2-, where Ru can be alkyl, aryl, cycloalkyl, and heterocyclyl, e.g., alkylsulfonyl. The term "alkylsulfonyl" as used herein refers to an alkyl group attached to a sulfonyl group. [0036] The term "oxo" is art-recognized and refers to a "=O" substituent. For example, 15 cyclopentane susbsituted with an oxo group is cyclopentanone. [0037] The symbol "~~u" indicates a point of attachment. [0038] The compounds of the disclosure may contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers. The term "stereoisomers" when used herein consist of all geometric isomers, 20 enantiomers or diastereomers. These compounds may be designated by the symbols "R" or "S," depending on the configuration of substituents around the stereogenic carbon atom. Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated "(±)" in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. Unless indicated otherwise, generic 25 chemical structures and graphical representations of specific compounds encompass all stereoisomers. [0039] Individual stereoisomers of compounds of the present invention can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well WO 2012/078867 PCT/US2011/063943 - 10 known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, or 5 (3) direct separation of the mixture of optical enantiomers on chiral chromatographic columns. Stereoisomeric mixtures can also be resolved into their component stereoisomers by well known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Stereoisomers can also be obtained from stereomerically-pure 10 intermediates, reagents, and catalysts by well known asymmetric synthetic methods. [0040] Geometric isomers can also exist in the compounds of the present invention. The symbol -- denotes a bond that may be a single, double or triple bond as described herein. The present invention encompasses the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of 15 substituents around a carbocyclic ring. Substituents around a carbon-carbon double bond are designated as being in the "Z" or "E" configuration wherein the terms "Z" and "E" are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the "E" and "Z" isomers. [0041] Substituents around a carbon-carbon double bond alternatively can be referred to as 20 "cis" or "trans," where "cis" represents substituents on the same side of the double bond and "trans" represents substituents on opposite sides of the double bond. The arrangement of substituents around a carbocyclic ring are designated as "cis" or "trans." The term "cis" represents substituents on the same side of the plane of the ring and the term "trans" represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the 25 substituents are disposed on both the same and opposite sides of plane of the ring are designated "cis/trans." [0042] Certain compounds described herein may exist as a single tautomer or as a mixture of tautomers. For example, certain guanidine compounds having a hydrogen atom attached to at least one of the guanidine nitrogen atoms can exist as a single tautomer or a mixture of 30 tautomers. To illustrate, depending upon the substituents attached at the R , R 2 and R 3 WO 2012/078867 PCT/US2011/063943 - 11 positions, the guanidine compound may exist as a single tautomer represented by A, B, or C, or as mixture of two or more of A, B, and C. I'lR2 /oR 2 R 2 N HN H H N H H HN NN N N N N I I I I I I R 1 R3 R 1 R3 R 1 R3 A B C [0043] The compounds disclosed herein can exist in solvated as well as unsolvated forms 5 with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. In one embodiment, the compound is amorphous. In one embodiment, the compound is a polymorph. In another embodiment, the compound is in a crystalline form. [0044] The invention also embraces isotopically labeled compounds of the invention which 10 are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 0, 0, 32 P, 35S, F, and 36Cl, respectively. 15 [0045] Certain isotopically-labeled disclosed compounds (e.g., those labeled with 3H and 14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo 20 half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labeled compounds of the invention can generally be prepared by following procedures analogous to those disclosed in the e.g., Examples herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. [0046] The term "IC 50 " is art-recognized and refers to the concentration of a compound that is 25 required for 50% inhibition of its target.
WO 2012/078867 PCT/US2011/063943 - 12 [0047] The term "EC 50 " is art-recognized and refers to the concentration of a compound at which 50% of its maximal effect is observed. [0048] The terms "subject" and "patient" refer to organisms to be treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals 5 (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and most preferably includes humans. In the context of the invention, the terms "subject" and "patient" generally refer to an individual who will receive or who has received treatment (e.g., administration of a compound of the present invention and optionally one or more other agents) for a condition characterized by the dysregulation of apoptotic processes. 10 [0049] As used herein, the term "effective amount" refers to the amount of a compound sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. As used herein, the term "treating" includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the 15 improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof. [0050] The phrase "pathologically proliferating or growing cells" refers to a localized population of proliferating cells in an animal that is not governed by the usual limitations of normal growth. 20 [0051] As used herein, the term "un-activated target cell" refers to a cell that is either in the Go phase or one to which a stimulus has not been applied. [0052] As used herein, the term "activated target lymphoid cell" refers to a lymphoid cell that has been primed with an appropriate stimulus to cause a signal transduction cascade, or alternatively, a lymphoid cell that is not in Go phase. Activated lymphoid cells may proliferate, 25 undergo activation induced cell death, or produce one or more cytotoxins, cytokines, or other related membrane-associated proteins characteristic of the cell type (e.g., CD8+ or CD4+). They are also capable of recognizing and binding any target cell that displays a particular antigen on its surface, and subsequently releasing its effector molecules.
WO 2012/078867 PCT/US2011/063943 - 13 [0053] As used herein, the term "activated cancer cell" refers to a cancer cell that has been primed with an appropriate stimulus to cause signal transduction. An activated cancer cell may or may not be in the Go phase. [0054] An activating agent is a stimulus that upon interaction with a target cell results in a 5 signal transduction cascade. Examples of activating stimuli include, but are not limited to, small molecules, radiant energy, and molecules that bind to cell activation cell surface receptors. Responses induced by activation stimuli can be characterized by changes in, among others, intracellular Ca 2 , superoxide, or hydroxyl radical levels; the activity of enzymes like kinases or phosphatases; or the energy state of the cell. For cancer cells, activating agents also 10 include transforming oncogenes. [0055] As used herein, the term "dysregulation of the process of cell death" refers to any aberration in the ability (e.g., predisposition) of a cell to undergo cell death via either necrosis or apoptosis. Dysregulation of cell death is associated with or induced by a variety of conditions, including for example, immune disorders (e.g., systemic lupus erythematosus, 15 autoimmune disorders, rheumatoid arthritis, graft-versus-host disease, myasthenia gravis, Sjdgren's syndrome, etc.), chronic inflammatory conditions (e.g., psoriasis, asthma and Crohn's disease), hyperproliferative disorders (e.g., tumors, B cell lymphomas, T cell lymphomas, etc.), viral infections (e.g., herpes, papilloma, HIV), and other conditions such as osteoarthritis and atherosclerosis. 20 [0056] It should be noted that when the dysregulation is induced by or associated with a viral infection, the viral infection may or may not be detectable at the time dysregulation occurs or is observed. That is, viral-induced dysregulation can occur even after the disappearance of symptoms of viral infection. [0057] A "hyperproliferative disorder," as used herein refers to any condition in which a 25 localized population of proliferating cells in an animal is not governed by the usual limitations of normal growth. Examples of hyperproliferative disorders include tumors, neoplasms, lymphomas and the like. A neoplasm is said to be benign if it does not undergo invasion or metastasis and malignant if it does either of these. A metastatic cell or tissue means that the cell can invade and destroy neighboring body structures. Hyperplasia is a form of cell 30 proliferation involving an increase in cell number in a tissue or organ, without significant alteration in structure or function. Metaplasia is a form of controlled cell growth in which one WO 2012/078867 PCT/US2011/063943 - 14 type of fully differentiated cell substitutes for another type of differentiated cell. Metaplasia can occur in epithelial or connective tissue cells. A typical metaplasia involves a somewhat disorderly metaplastic epithelium. [0058] The pathological growth of activated lymphoid cells often results in an immune 5 disorder or a chronic inflammatory condition. As used herein, the term "immune disorder" refers to any condition in which an organism produces antibodies or immune cells which recognize the organism's own molecules, cells or tissues. Non-limiting examples of immune disorders include autoimmune disorders, immune hemolytic anemia, immune hepatitis, Berger's disease or IgA nephropathy, Celiac Sprue, chronic fatigue syndrome, Crohn's disease, 10 dermatomyositis, fibromyalgia, graft versus host disease, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjorgren syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, vitiligo, tuberculosis, and the like. 15 [0059] As used herein, the term "chronic inflammatory condition" refers to a condition wherein the organism's immune cells are activated. Such a condition is characterized by a persistent inflammatory response with pathologic sequelae. This state is characterized by infiltration of mononuclear cells, proliferation of fibroblasts and small blood vessels, increased connective tissue, and tissue destruction. Examples of chronic inflammatory diseases include, 20 but are not limited to, Crohn's disease, psoriasis, chronic obstructive pulmonary disease, inflammatory bowel disease, multiple sclerosis, and asthma. Immune diseases such as rheumatoid arthritis and systemic lupus erythematosus can also result in a chronic inflammatory state. [0060] As used herein, the term "co-administration" refers to the administration of at least 25 two agent(s) (e.g., a compound of the present invention) or therapies to a subject. In some embodiments, the co-administration of two or more agents/therapies is concurrent. In other embodiments, a first agent/therapy is administered prior to a second agent/therapy. Those of skill in the art understand that the formulations and/or routes of administration of the various agents/therapies used may vary. The appropriate dosage for co-administration can be readily 30 determined by one skilled in the art. In some embodiments, when agents/therapies are co administered, the respective agents/therapies are administered at lower dosages than WO 2012/078867 PCT/US2011/063943 - 15 appropriate for their administration alone. Thus, co-administration is especially desirable in embodiments where the co-administration of the agents/therapies lowers the requisite dosage of a known potentially harmful (e.g., toxic) agent(s). [0061] As used herein, the term "pharmaceutical composition" refers to the combination of an 5 active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo. [0062] As used herein, the term "pharmaceutically acceptable carrier" refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents. The 10 compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants. (See e.g., Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA [1975]). [0063] As used herein, the term "pharmaceutically acceptable salt" refers to any pharmaceutically acceptable salt (e.g., acid or base) of a compound of the present invention 15 which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof. As is known to those of skill in the art, "salts" of the compounds of the present invention may be derived from inorganic or organic acids and bases. Examples of acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, 20 tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene 2-sulfonic, benzenesulfonic acid, and the like. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts. 25 [0064] Examples of bases include, but are not limited to, alkali metals (e.g., sodium) hydroxides, alkaline earth metals (e.g., magnesium), hydroxides, ammonia, and compounds of formula NW 4 ', wherein W is Cp4 alkyl, and the like. [0065] Examples of salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, 30 cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, WO 2012/078867 PCT/US2011/063943 - 16 hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2 naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like. Other examples of salts include anions of the compounds of the present invention compounded 5 with a suitable cation such as Nat, NH 1 4, and NW 4 ' (wherein W is a C 1
.
4 alkyl group), and the like. [0066] For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non pharmaceutically acceptable may also find use, for example, in the preparation or purification 10 of a pharmaceutically acceptable compound. [0067] As used herein, the term "modulate" refers to the activity of a compound (e.g., a compound of the present invention) to affect (e.g., to promote or retard) an aspect of cellular function, including, but not limited to, cell growth, proliferation, apoptosis, and the like. [0068] Throughout the description, where compositions are described as having, including, or 15 comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps. 20 [0069] As a general matter, compositions specifying a percentage are by weight unless otherwise specified. Further, if a variable is not accompanied by a definition, then the previous definition of the variable controls. HI. Modulators of F 1
F
0 -ATPase Activity [0070] In some embodiments, the present invention regulates FiFo-ATPase activity (e.g., 25 mitochondrial FiFo-ATPase activity) through the exposure of cells to compounds of the present invention. In some embodiments, the compounds inhibit ATP synthesis and ATP hydrolysis. The effect of the compounds can be measured by detecting any number of cellular changes. For example, mitochondrial FiFo-ATPase activity and/or cell death may be assayed as described herein and in the art. In some embodiments, cell lines are maintained under 30 appropriate cell culturing conditions (e.g., gas (CO 2 ), temperature and media) for an WO 2012/078867 PCT/US2011/063943 - 17 appropriate period of time to attain exponential proliferation without density dependent constraints. Cell number and or viability are measured using standard techniques, such as trypan blue exclusion/hemo-cytometry, or an Alamar Blue or MTT dye conversion assay. Alternatively, the cell may be analyzed for the expression of genes or gene products associated 5 with aberrations in apoptosis or necrosis. [0071] In some embodiments, exposing the compounds of the present invention to a cell induces apoptosis. In some embodiments, the present invention induces apoptosis or arrest of cell proliferation through interacting with the mitochondrial FiFo-ATPase. In some embodiments, the compounds of the present invention inhibit mitochondrial FiFo-ATPase 10 activity through binding the OSCP. In some embodiments, the compounds of the present invention bind the junction between the OSCP and the F 1 subunit of the mitochondrial FIFO ATPase. In some embodiments, the compounds of the present invention bind the F 1 subunit. In certain embodiments, screening assays of the present invention permit detection of binding partners of the OSCP, F 1 , or OSCP/F 1 junction. 15 [0072] In some embodiments, exposing a compound of the present invention to a cell induces apoptosis. In some embodiments, the present invention causes an initial increase in cellular ROS levels (e.g., 02~). In further embodiments, exposure of the compounds of the present invention to a cell causes an increase in cellular 02~ levels. In still further embodiments, the increase in cellular O2 levels resulting from the compounds of the present invention is 20 detectable with a redox-sensitive agent that reacts specifically with 02~ (e.g., dihydroethidium (DHE)). [0073] In some embodiments, the present invention causes a collapse of a cell's mitochondrial transmembrane potential (ATm). In some embodiments, a collapse of a cell's mitochondrial ATm resulting from the present invention is detectable with a mitochondria 25 selective potentiometric probe (e.g., 3,3'-Dihexyloxacarbocyanine iodide, DiOC 6 ). In further embodiments, a collapse of a cell's mitochondrial ATm resulting from the present invention occurs after an initial increase in cellular 02 levels. [0074] In some embodiments, the present invention enables caspase activation. In other embodiments, the present invention causes the release of cytochrome c from mitochondria. In 30 further embodiments, the present invention alters cystolic cytochrome c levels. In still other embodiments, altered cystolic cytochrome c levels resulting from the present invention are WO 2012/078867 PCT/US2011/063943 - 18 detectable by immunoblotting cytosolic fractions. In some embodiments, diminished cystolic cytochrome c levels resulting from the present invention are detectable after a period of time (e.g., 10 hours). In further preferred embodiments, diminished cystolic cytochrome c levels resulting from the present invention are detectable after 5 hours. 5 [0075] In other embodiments, the present invention causes the opening of the mitochondrial permeability transition pore. In some embodiments, the cellular release of cytochrome c resulting from the present invention is consistent with a collapse of mitochondrial ATm. In still further preferred embodiments, the present invention causes an increase in cellular 02 levels after a mitochondrial ATm collapse and a release of cytochrome c. In further preferred 10 embodiments, a rise in cellular 02 levels is caused by a mitochondrial ATm collapse and release of cytochrome c resulting from the present invention. [0076] In other embodiments, the present invention causes cellular caspase activation. In some embodiments, caspase activation resulting from the present invention is measurable with a pan-caspase sensitive fluorescent substrate (e.g., FAM-VAD-fmk). In still further 15 embodiments, caspase activation resulting from the present invention tracks with a collapse of mitochondrial ATm. In other embodiments, the present invention causes an appearance of hypodiploid DNA. In some embodiments, an appearance of hypodiploid DNA resulting from the present invention is slightly delayed with respect to caspase activation. [0077] In some embodiments, the molecular target for the present invention is found within 20 mitochondria. In further embodiments, the molecular target of the present invention involves the mitochondrial ATPase. The primary sources of cellular ROS include redox enzymes and the mitochondrial respiratory chain (hereinafter MRC). In some embodiments, cytochrome c oxidase (complex IV of the MRC) inhibitors (e.g., NaN 3 ) preclude a present invention dependent increase in cellular ROS levels. In other preferred embodiments, the ubiquinol 25 cytochrome c reductase component of MRC complex III inhibitors (e.g., FK506) preclude a present invention dependent increase in ROS levels.
WO 2012/078867 PCT/US2011/063943 - 19 III. Guanidine Compounds [0078] In one aspect, the invention provides a family of compounds represented by Formula I: 0 N (R1)n c rR2 R 2..N N R4 &R3 5 including all stereoisomers, geometric isomers, and tautomers; or a pharmaceutically acceptable salt or solvate of any of the foregoing; wherein: A is cycloalkylene; R represents independently for each occurrence halogen, haloalkyl, alkyl, cycloalkyl, 10 heterocycloalkyl, hydroxyl, CI-C 6 alkoxy, cyano, -CO 2
R
9 , -C(O)R , -S(O)R , -SO 2 R ,
-SO
2
N(R
1 ")(R 1 2 ), -C(O)N(R")(R 12 ), -N(R 11 )(R 12 ), or -N(R9)C(O)(R );
R
2 represents independently for each occurrence hydrogen or alkyl;
R
3 is -N(R 5
)CO
2 R 6, -N(R 5 )C(O)R , -N(R )C(O)N(R 7)(R ), -N(R 5
)SO
2 R 6, -N(R 7)(R), -OC(O)N(R 7)(R ), -OC(O)R , -OR', -C(O)N(R 7 )(R'), -C0 2
R
5 , -C(O)R 5 , oxo, alkyl, haloalkyl, 15 or heterocyclyl;
R
4 is aryl, aralkyl, cycloalkyl, -alkylene-cycloalkyl, alkyl, or haloalkyl, wherein said aryl, aralkyl, and cycloalkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, cycloalkyl, C1
C
6 alkoxy, -N(R 5
)CO
2 R 6, and -N(R 5 )C(O)R6 20 R 5 represents independently for each occurrence hydrogen, alkyl, cycloalkyl, haloalkyl, or heterocycloalkyl; R represents independently for each occurrence alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heterocyclyl, or -alkylene-heterocyclyl; WO 2012/078867 PCT/US2011/063943 - 20 R7 and R8 each represent independently for each occurrence hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkenylene, aryl, or heterocyclyl; or R7 and R8 are taken together with the nitrogen to which they are attached to form a 3-7 membered heterocyclic ring;
R
9 represents independently for each occurrence hydrogen, alkyl, or cycloalkyl; 5 R 10 represents independently for each occurrence alkyl or cycloalkyl; R"I and R 12 each represent independently for each occurrence hydrogen, alkyl, or cycloalkyl; or R"I and R 12 are taken together with the nitrogen atom to which they are attached to form a 3 to 7 membered heterocyclic ring optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, hydroxyl, alkyl, 10 cycloalkyl, and CI-C 6 alkoxy; and n is 0, 1, 2, or 3. [0079] In certain embodiments, the compound is a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof. [0080] In certain embodiments, A is cycloalkylene, that in addition to R 3 , is optionally 15 substituted with 1 or 2 substituents independently selected from the group consisting of halogen, alkyl, haloalkyl, cycloalkyl, heterocycyl, -N(R 5 )C0 2
R
6 , -N(R 5 )C(O)R ,
-N(R
5
)C(O)N(R
7 )(R), -N(R')SO 2 R 6, -N(R 7)(R ), -OC(O)N(R 7)(R ), -OC(O)R , -OR', 7 855 -C(O)N(R )(R'), -CO 2 R', and -C(O)R . In certain other embodiments, A is cycloalkylene, that in addition to R 3 , is optionally substituted with 1 or 2 substituents independently selected from 20 the group consisting of halogen, alkyl, haloalkyl, cycloalkyl, -N(R 5
)CO
2 R , -N(R )C(O)R , -N(R 7)(R ), -OC(O)N(R 7)(R ), -OC(O)R , -OR , -C(O)N(R 7)(R'), and -CO 2 R5. In certain other embodiments, A is cycloalkylene, that in addition to R 3 , is optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, alkyl, haloalkyl, 5 6 5 6 7 8 5 5 cycloalkyl, -N(R )CO 2 R , -N(R )C(O)R , -N(R )(R'), -OR , and -C(O)R . In certain other 25 embodiments, A is cyclobutylene, cyclopentylene, or cyclohexylene. In certain other embodiments, A is cyclobutylene, cyclopentylene, or cyclohexylene, each of which, in addition 3 to R , is optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, alkyl, haloalkyl, hydroxyl, and -N(R 7)(R ). In certain other embodiments, A is cyclobutylene, cyclopentylene, or cyclohexylene. In certain other 30 embodiments, A is cyclohexylene.
WO 2012/078867 PCT/US2011/063943 - 21 [0081] In certain embodiments, R represents independently for each occurrence halogen, alkyl, haloalkyl, cyano, hydroxyl, CI-C 6 alkoxy, or -SO 2 -C1-C 6 alkyl. In certain other embodiments, R represents independently for each occurrence halogen, alkyl, haloalkyl, cyano, hydroxyl, or C 1
-C
6 alkoxy. In certain other embodiments, R represents independently 5 for each occurrence halogen, haloalkyl, alkyl, or CI-C 6 alkoxy. In certain other embodiments, R represents independently for each occurrence halogen or haloalkyl. In certain other embodiments, R represents independently for each occurrence chloro, fluoro, or trifluoromethyl. In certain other embodiments, R 1 is fluoro attached at meta and para positions of the phenyl ring, and n is 2. In certain other embodiments, R is chloro attached at the para 10 position of the phenyl ring, and n is 1. In certain embodiments, R 2 is hydrogen. In certain other embodiments, R 2 is methyl. [0082] In certain embodiments, R3 is -N(R 5
)CO
2 R 6, -N(R )C(O)R , -N(R 5
)C(O)N(R
7 )(R),
-N(R
5
)SO
2 R 6, -N(R 7
)(R
8 ), -OC(O)N(R 7 )(R), -OC(O)R , -OR', -C(O)N(R 7)(R'), -CO 2 R', 5 3 56 -C(O)R , alkyl, haloalkyl, or heterocyclyl. In certain other embodiments, R is -N(R 5
)CO
2 R , 15 -N(R 5
)C(O)R
6 , -N(R 5
)C(O)N(R
7 )(R), -N(R 5
)SO
2 R6, -N(R 7 )(R'), -OC(O)N(R 7 )(R'), -OC(O)R 6 , -OR , -C(O)N(R 7 )(R'), or -CO 2 R6. In certain other embodiments, R 3 is -N(R 5
)CO
2 R6, -N(R5)C(O)R6, -N(R 5)C(O)N(R 7)(R ), -N(R 5)SO 2 R 6, or -N(R 7)(R). In certain other embodiments, R3 is -N(R 5
)CO
2 R 6. In certain embodiments, R3 is -N(R 7)(R ). In certain other embodiments, R3 is -N(R 5 )C(O)R , -N(R 5
)C(O)N(R
7 )(R), or -N(R 5)SO 2 R 6. In certain other 20 embodiments, R 3 is -N(R 5
)C(O)R
6 . In certain other embodiments, R 3 is -N(R 5
)C(O)N(R
7 )(R) or -N(R 5)SO 2 R 6. In certain other embodiments, R3 is -OC(O)N(R 7 )(R'), -OC(O)R , or -OR5. In certain other embodiments, R 3 is -C(O)N(R 7 )(R) or -CO 2
R
5 . [0083] In certain other embodiments, R 3 is -N(H)CO 2
CH
3 or -N(H)CO 2
CH
2
CH
3 . In certain other embodiments, R 3 is -N(H)C(O)-(C 1
-C
6 )alkyl, -N(H)C(O)-(unsubstituted aryl), or 25 -N(H)C(O)-(unsubstituted heteroaryl). In certain other embodiments, R 3 is
-N(H)C(O)N(H)(CI-C
6 )alkyl or -N(H)SO 2
(CI-C
6 )alkyl. In certain other embodiments, R3 is -OH. In certain other embodiments, R 3 is -N(H)(5-6 membered unsubstituted heterocyclyl). [0084] In certain embodiments, R 4 is aryl, aralkyl, cycloalkyl, -alkylene-cycloalkyl, alkyl, or haloalkyl, wherein said aryl, aralkyl, and cycloalkyl are each optionally substituted with 1, 2, or 30 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, cycloalkyl, and C 1
-C
6 alkoxy. In certain other embodiments, R 4 is aryl or aralkyl, each of which WO 2012/078867 PCT/US2011/063943 - 22 is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, cycloalkyl, and C1-C 6 alkoxy. In certain other embodiments, R 4 is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, cycloalkyl, and C 1
-C
6 alkoxy. 5 In certain other embodiments, R 4 is phenyl substituted with 1, 2, or 3 substituents independently selected from the group consisting of chloro, fluoro, trifluoromethyl, cyclopropyl, and (C 1
-C
4 )alkyl. In certain other embodiments, R 4 is phenyl substituted with 1 or 2 substituents independently selected from the group consisting of chloro, fluoro, and trifluoromethyl. In certain other embodiments, R 4 is benzyl substituted with 1, 2, or 3 10 substituents independently selected from the group consisting of chloro, fluoro, trifluoromethyl, cyclopropyl, and (CI-C 4 )alkyl. In certain other embodiments, R 4 is benzyl substituted with 1 or 2 substituents independently selected from the group consisting of chloro, fluoro, trifluoromethyl, cyclopropyl, and (C 1
-C
4 )alkyl. [0085] In certain embodiments, R5 represents independently for each occurrence hydrogen or 15 (C1-C4)alkyl. In certain embodiments, R6 represents independently for each occurrence (C1
C
4 )alkyl, (C 3
-C
7 )cycloalkyl, or haloalkyl. In certain embodiments, R represents independently for each occurrence methyl, ethyl, cyclopropyl, or trifluoromethyl. In certain embodiments, R 6 is heterocyclyl. In certain embodiments, R is heteroaryl, such as pyridinyl or thiazolyl. [0086] In certain embodiments, R7 and R8 each represent independently for each occurrence 20 hydrogen, alkyl, cycloalkyl, or heterocyclyl. In certain other embodiments, R 7 is hydrogen, and
R
8 is hydrogen, methyl, ethyl, propyl, or butyl. In certain other embodiments, R 7 is hydrogen, and R 8 is a 6-membered aromatic heterocyclyl. [0087] In certain embodiments, n is 1 or 2. In certain other embodiments, n is 2. In certain embodiments, n is 0.
WO 2012/078867 PCT/US2011/063943 - 23 [0088] Another aspect of the invention provides a family of compounds represented by Formula IA: 0 r N (R')n CR 2 R4 &R3 IA 5 including all stereoisomers, geometric isomers, and tautomers; or a pharmaceutically acceptable salt or solvate of any of the foregoing; wherein: A is cycloalkylene; R represents independently for each occurrence halogen, alkyl, haloalkyl, cyano, hydroxyl, or C 1
-C
6 alkoxy; 10 R 2 represents independently for each occurrence hydrogen or alkyl;
R
3 is -N(R 5
)CO
2 R 6, -N(R 5 )C(O)R , -N(R )C(O)N(R 7)(R ), -N(R 5
)SO
2 R 6, -N(R 7)(R), -OC(O)N(R 7)(R ), -OC(O)R , -OR', -C(O)N(R 7 )(R'), -C0 2
R
5 , -C(O)R 5 , alkyl, haloalkyl, or heterocyclyl;
R
4 is aryl, aralkyl, cycloalkyl, -alkylene-cycloalkyl, alkyl, or haloalkyl, wherein said 15 aryl, aralkyl, and cycloalkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, cycloalkyl, and
C
1
-C
6 alkoxy;
R
5 represents independently for each occurrence hydrogen, alkyl, cycloalkyl, haloalkyl, or heterocycloalkyl; 20 R represents independently for each occurrence alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heterocyclyl, or -alkylene-heterocyclyl; R7 and R8 each represent independently for each occurrence hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkenylene, aryl, or heterocyclyl; or R7 and R8 are taken together with the nitrogen to which they are attached to form a 3-7 membered heterocyclic ring; and 25 nis0,1,2,or3.
WO 2012/078867 PCT/US2011/063943 - 24 [0089] In certain embodiments, the compound is a compound of Formula I-A or a pharmaceutically acceptable salt or solvate thereof. In certain other embodiments, variables A,
R
1 through R 8 , and/or n for Formula I-A are as defined by one of the further embodiments specified above in connection with Formula I, such as where A is cyclohexylene; R represents 5 independently for each occurrence halogen, haloalkyl, alkyl, or C1-C 6 alkoxy; R 2 is hydrogen; and R3 is -N(R 5
)CO
2 R 6, -N(R )C(O)R , -N(R 5
)C(O)N(R
7 )(R'), -N(R')SO 2 R 6, or -N(R 7)(R). [0090] Another aspect of the invention provides a compound represented by Formula I-Al: 0 R \ N 2 HN NH R R3 (I-Al) 10 including all stereoisomers, geometric isomers, and tautomers; or a pharmaceutically acceptable salt or solvate of any of the foregoing; wherein: R and R2 each represent independently hydrogen, chloro, fluoro, -CF 3 , methyl, or methoxyl;
R
3 is -N(R 5
)CO
2 R 6, -N(R 5 )C(O)R , -N(R )C(O)N(R 7)(R'), -N(R 5
)SO
2 R 6, -N(R 7)(R), 15 -OC(O)N(R 7)(R'), -OC(O)R , -OH, -C(O)N(R 7 )(R), -C0 2
R
5 , haloalkyl, or heterocyclyl;
R
4 is aryl, aralkyl, cycloalkyl, -alkylene-cycloalkyl, alkyl, or haloalkyl, wherein said aryl, aralkyl, and cycloalkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, cycloalkyl, and C1-C 6 alkoxy; 20 R 5 represents independently for each occurrence hydrogen, alkyl, cycloalkyl, haloalkyl, or heterocycloalkyl; R represents independently for each occurrence alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heterocyclyl, or -alkylene-heterocyclyl; and WO 2012/078867 PCT/US2011/063943 - 25 R7 and R8 each represent independently for each occurrence hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkenylene, aryl, or heterocyclyl; or R7 and R8 are taken together with the nitrogen to which they are attached to form a 3-7 membered heterocyclic ring. [0091] In certain embodiments, the compound is a compound of Formula I-Al or a 5 pharmaceutically acceptable salt or solvate thereof. [0092] In certain embodiments, R and R 2 are chloro or fluoro. In certain other embodiments, R and R 2 are fluoro. In certain embodiments, R and R 2 are chloro. In certain other embodiments, R 1 is trifluoromethyl, and R 2 is hydrogen. [0093] In certain embodiments, R3 is -N(R 5
)CO
2 R 6; R is hydrogen or methyl; and R6 is 10 methyl, ethyl, propyl or butyl. In certain other embodiments, R 3 is -N(R 5 )C0 2
R
6 , -N(R 5)C(O)R 6, -N(R 5)C(O)N(R 7)(RS), -N(R 5)SO2R 6, -N(R 7)(RS), -OC(O)N(R 7)(RS), -OC(O)R 6, -OR , -C(O)N(R 7 )(R), or -CO 2 R 6. In certain other embodiments, R 3 is -N(R 5
)CO
2 R6, -N(R5)C(O)R6, -N(R 5)C(O)N(R 7)(R), -N(R 5)SO 2 R 6, or -N(R 7)(R). In certain other embodiments, R3 is -N(R 5
)CO
2 R 6. In certain embodiments, R3 is -N(R 7)(R ). In certain other 15 embodiments, R3 is -N(R 5 )C(O)R , -N(R 5
)C(O)N(R
7 )(R), or -N(R 5
)SO
2 R 6. In certain other embodiments, R 3 is -OC(O)N(R 7 )(R), -OC(O)R 6 , or -OR 5 . In certain other embodiments, R 3 is 7 85 -C(O)N(R )(R8) or -CO 2 R. [0094] In certain other embodiments, R 3 is -N(H)CO 2
CH
3 or -N(H)CO 2
CH
2
CH
3 . In certain other embodiments, R 3 is -N(H)C(O)-(C 1
-C
6 )alkyl, -N(H)C(O)-(unsubstituted aryl), or 20 -N(H)C(O)-(unsubstituted heteroaryl). In certain other embodiments, R 3 is
-N(H)C(O)N(H)(C
1
-C
6 )alkyl or -N(H)SO 2
)(C
1
-C
6 )alkyl. In certain other embodiments, R 3 is -OH. In certain other embodiments, R 3 is -N(H)(5-6 membered unsubstituted heterocyclyl). [0095] In certain embodiments, R 4 is phenyl substituted with 1 or 2 substituents independently selected from the group consisting of chloro, fluoro, and trifluoromethyl. In 25 certain other embodiments, R 4 is aryl or aralkyl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, and cycloalkyl. In certain other embodiments, R 4 is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, and cycloalkyl. In certain other embodiments, R 4 is phenyl substituted with 1, 2, or 3 30 substituents independently selected from the group consisting of chloro, fluoro, trifluoromethyl, cyclopropyl, and (CI-C 4 )alkyl. In certain other embodiments, R 4 is phenyl substituted with 1 or WO 2012/078867 PCT/US2011/063943 - 26 2 substituents independently selected from the group consisting of chloro, fluoro, and trifluoromethyl. In certain other embodiments, R 4 is benzyl substituted with 1, 2, or 3 substituents independently selected from the group consisting of chloro, fluoro, trifluoromethyl, cyclopropyl, and (CI-C 4 )alkyl. In certain other embodiments, R 4 is benzyl substituted with 1 or 5 2 substituents independently selected from the group consisting of chloro, fluoro, trifluoromethyl, cyclopropyl, and (C 1
-C
4 )alkyl. [0096] In certain embodiments, R5 represents independently for each occurrence hydrogen or (C1-C4)alkyl. In certain embodiments, R6 represents independently for each occurrence (C1
C
4 )alkyl, (C 3
-C
7 )cycloalkyl, or haloalkyl. In certain embodiments, R represents independently 10 for each occurrence methyl, ethyl, cyclopropyl, or trifluoromethyl. In certain embodiments, R 6 is heterocyclyl. In certain embodiments, R is heteroaryl, such as pyridinyl or thiazolyl. [0097] In certain embodiments, R7 and R8 each represent independently for each occurrence hydrogen, alkyl, cycloalkyl, or heterocyclyl. In certain other embodiments, R 7 is hydrogen, and
R
8 is hydrogen, methyl, ethyl, propyl, or butyl. In certain other embodiments, R 7 is hydrogen, 15 and R 8 is a 6-membered aromatic heterocyclyl. [0098] The description above describes multiple embodiments providing definitions for variables used herein. The application specifically contemplates all combinations of such variables, e.g., particular combinations of the definitions set forth for variables R and A of Formula I, where R 1 fluoro, and A is cyclohexylene. 20 [0099] In certain other embodiments, the compound is one of the compounds listed in Tables 1-2 below or Table 3 in Example 4, or a pharmaceutically acceptable salt thereof. It is understood that the foregoing compounds can be combined with a pharmaceutically acceptable carrier to produce a pharmaceutical composition.
WO 2012/078867 PCT/US2011/063943 - 27 TABLE 1 0 A-k HN NH -?iz x Y No. A X Y Z I-1 4-chlorophenyl 4-N(H)CO 2
CH
3 2-H 3-chlorophenyl 1-2 3-chlorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H 4-chlorophenyl 1-3 4-fluorophenyl 4-N(H)CO 2
CH
3 2-H 3-chlorophenyl 1-4 3-fluorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H 4-chlorophenyl 1-5 3,4-dichlorophenyl 4-N(H)CO 2
CH
3 2-H 3-chlorophenyl 1-6 3,4-difluorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H 4-chlorophenyl 1-7 4-trifluoromethylphenyl 4-N(H)CO 2
CH
2
CH
3 2-H 3-cyclopropylphenyl 1-8 4-chlorophenyl 4-N(H)C(O)CH 3 2-H 3,5-dichlorophenyl 1-9 3-chlorophenyl 4-N(H)C(O)CH 3 2-H 3,5-dichlorophenyl 1-10 4-fluorophenyl 4-N(H)C(O)CH 3 2-H 3,5-dichlorophenyl I-11 3-fluorophenyl 4-N(H)C(O)CF 3 2-H 3-chloro-5-fluorophenyl 1-12 3,4-dichlorophenyl 4-N(H)C(O)-cyclopropyl 2-H 3-chloro-5-fluorophenyl 1-13 3,4-difluorophenyl 4-N(H)C(O)-phenyl 2-H 3-chloro-5-fluorophenyl 1-14 4-trifluoromethylphenyl 4-N(H)C(O)-benzyl 2-H 3-chloro-5-fluorophenyl N 1-15 4-chlorophenyl 4-N(H) -<\ 2-H 3-chlorophenyl N NH I-16 3-chlorophenyl 4-N(H)-O 2-H 4-chlorophenyl 1-17 4-fluorophenyl 4-N(H) N 2-H 3-chlorophenyl 0 1-18 3-fluorophenyl 4-N(CH 3 ) 2-CH 3 4-chlorophenyl 1-19 3,4-dichlorophenyl 3-N(H) N 2-CH 3 3-chlorophenyl NH I-20 3,4-difluorophenyl 4-N(CH3) 2-H 4-chlorophenyl WO 2012/078867 PCT/US2011/063943 -28 No. A X Y Z 0 1-21 4-trifluoromethylphenyl 4-N(CH 3 ) 2-H 3-chlorophenyl 1-22 4-chlorophenyl 4-N(H) 2-H 4-chlorophenyl 4-N(H) 1-23 3-chlorophenyl 2-H 3-chlorophenyl 4-N(H) N 1-24 4-fluorophenyl / 2-H 4-chlorophenyl H 1-26 3,4-dichlorophenyl 4-N(H) 2-H 4-chlorophenyl 1-27 3,4-difluorophenyl 4-NH 2 2-H 3-chlorophenyl 1-28 4-trifluoromethylphenyl 4-N(H)CH 3 2-H 4-chlorophenyl 1-29 4-chlorophenyl 4-N(H)CO 2
CH
3 2-H 2-trifluoromethylphenyl 1-30 3-chlorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H 2-trifluoromethylphenyl 1-31 4-fluorophenyl 4-N(H)CO 2
CH
3 2-H 2-trifluoromethylphenyl 1-32 3-fluorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H 2-tert-butylphenyl 1-33 3,4-dichlorophenyl 4-N(H)CO 2
CH
3 2-H 2-tert-butylphenyl 1-34 3,4-difluorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H 2-trifluoromethylphenyl -35 4-chlorophenyl N(H)C(O)H)CH 2
CH
3 2-H 3-chlorophenyl 1-36 3-chlorophenyl 4-N(H)C(O)N(H)-benzyl 2-H 4-chlorophenyl 1-37 4-fluorophenyl 4-N(H)SO 2
CH
2
CH
3 2-H 3-cyclopropylphenyl 1-38 3-fluorophenyl 4-N(H)SO 2 -benzyl 2-H 3,5-dichlorophenyl 1-39 3,4-dichlorophenyl 4-OC(O)N(H)CH 3 2-H 3,5-fluorophenyl 1-40 3,4-difluorophenyl 4-OC(O)N(H)-benzyl 2-H 3-cyclopropyl-5 1-41 4-chlorophenyl 4-OC(O)CH 2
CH
3 2-H 3-chlorophenyl 1-42 3-chlorophenyl 4-OH 2-H 4-chlorophenyl 1-43 4-fluorophenyl 4-OH 2-H 3-cyclopropylphenyl 1-44 3-fluorophenyl 3-OH 2-H 3,5-dichlorophenyl 1-45 3,4-dichlorophenyl 3-OH 2-H 3,5-fluorophenyl WO 2012/078867 PCT/US2011/063943 -29 No. A X Y Z 1-46 3,4-difluorophenyl 4-C(O)N(H)CH 2
CH
3 2-H 3-cyclopropyl-5 I-47 4-chlorophenyl 4-C(O)N(H)-cyclopropyl 2-H 3-chlorophenyl 1-48 3-chlorophenyl 4-C(O)N(H)CF 3 2-H 4-chlorophenyl 1-49 4-fluorophenyl 4-CO 2 H 2-H 3-cyclopropylphenyl 1-50 3-fluorophenyl 4-CO 2
CH
3 2-H 3,5-dichlorophenyl I-51 3,4-dichlorophenyl 4-C(O)CH 3 2-H 3,5-fluorophenyl 3-cyclopropyl-5 1-52 4-chiorophenyl 4-N(H)-N \ NH 3-CH 3 fluorophenyl 1-53 3-chlorophenyl 4-N(H) NH 3-CH 3 3-fluorophenyl 1-54 4-fluorophenyl 4-N(H) \ 3-CH 3 4-fluorophenyl 1-55 3,4-dichlorophenyl 3-CF 3 5-CF 3 3-fluorophenyl 1-56 4-chlorophenyl 3-N(H)CO 2
CH
3
N(CH
3
)
2 3-chlorophenyl 1-57 3-chlorophenyl 3-N(H)CO 2
CH
2
CH
3
N(CH
3
)
2 4-chlorophenyl I-58 4-chlorophenyl 4-N(H)CO 2
CH
3 2-H 3-chlorobenzyl 1-59 3-chlorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H 4-chlorobenzyl 1-60 4-fluorophenyl 4-N(H)CO 2
CH
3 2-H 3-fluorobenzyl 1-61 3-fluorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H 4-fluorobenzyl 1-62 3,4-dichlorophenyl 4-N(H)CO 2
CH
3 2-H 3-chloro-5-fluorobenzyl 1-63 3,4-difluorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H 3 ,5-dichlorobenzyl 1-64 4-trifluoromethylphenyl 4-N(H)CO 2
CH
2
CH
3 2-H 3,5-difluorobenzyl 1-65 4-chlorophenyl 4-N(H)CO 2
CH
3 2-H 3-cyclopropylbenzyl 1-66 3-chlorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H 3-trifluoromethylbenzyl 1-67 4-fluorophenyl 4-N(H)CO 2
CH
3 2-H 4-trifluoromethylbenzyl 1-68 3-fluorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H cyclopropyl 1-69 3,4-dichlorophenyl 4-N(H)CO 2
CH
3 2-H cyclopentyl 1-70 3,4-difluorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H cyclohexyl 1-71 4-trifluoromethylphenyl 4-N(H)CO 2
CH
2
CH
3 2-H 4-methylcyclohexyl 1-72 4-chlorophenyl 4-N(H)CO 2
CH
3 2-H ethyl 1-73 3-chlorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H tert-butyl 1-74 4-fluorophenyl 4-N(H)CO 2
CH
3 2-H 2,2,2-trifluoroethyl WO 2012/078867 PCT/US2011/063943 -30 No. A X Y Z 1-75 3-fluorophenyl 4-N(H)CO 2
CH
2
CH
3 2-H 1 -methylcyclobutyl TABLE 2 0 A4 N HN NH No. A u 11Z 11-1 4-chiorophenyl 2-N(H)CO 2
CH
3 1 4-fluorophenyl 11-2 3-chlorophenyl 2-N(H)CO 2
CH
2
CH
3 1 3-fluorophenyl 11-3 4-fluorophenyl 2-N(H)CO 2
CH
3 1 3,4-dichlorophenyl 11-4 3-fluorophenyl 2-N(H)CO 2
CH
2
CH
3 1 3,4-difluorophenyl 11-5 3,4-dichlorophenyl 2-N(H) -<x 1 4-trifluoromethylphenyl N D NH 11-6 3,4-difluorophenyl 2-N(H) / 1 4-fluorobenzyl 11-7 trifluoromethylphenyl 2-NH 2 1 3-fluorobenzyl 11-8 4-chlorophenyl 2-N(H)C(O)CH 3 1 3,4-dichlorobenzyl 11-9 3-chlorophenyl 2-N(H)C(O)-phenyl 1 3,4-difluorobenzyl 11-10 4-fluorophenyl 2-CF 3 1 4-trifluoromethylbenzyl 11-11 4-chlorophenyl 3-N(H)CO 2
CH
3 2 4-fluorophenyl 11-12 3-chlorophenyl 3-N(H)CO 2
CH
2
CH
3 2 3-fluorophenyl 11-13 4-fluorophenyl 3-N(H)CO 2
CH
3 2 3,4-dichlorophenyl 11-14 3-fluorophenyl 3-N(H)CO 2
CH
2
CH
3 2 3,4-difluorophenyl
N
11-15 3,4-dichlorophenyl 3-N(H) -< 2 4-trifluoromethylphenyl N 11-16 3,4-difluorophenyl 3-N(H) H/ 2 4-fluorobenzyl -17 trifluoromethyphenyl 3-NH 2 2 3-fluorobenzyl 11-18 4-chlorophenyl 3-N(H)C(O)CH 3 2 3,4-dichlorobenzyl WO 2012/078867 PCT/US2011/063943 -31 No. A X n Z 11-19 3-chlorophenyl 3-N(H)C(O)-phenyl 2 3,4-difluorobenzyl 11-20 4-fluorophenyl 3-CF 3 2 4-trifluoromethylbenzyl 11-21 4-chlorophenyl 4-N(H)CO 2
CH
3 3 4-fluorophenyl 11-22 3-chlorophenyl 4-N(H)CO 2
CH
2
CH
3 3 3-fluorophenyl 11-23 4-fluorophenyl 4-N(H)CO 2
CH
3 3 3,4-dichlorophenyl 11-24 3-fluorophenyl 4-N(H)CO 2
CH
2
CH
3 3 3,4-difluorophenyl N II-25 3,4-dichlorophenyl 4-N(H) <\3 4-trifluoromethylphenyl N H 11-26 3,4-difluorophenyl 4-N(H) N 3 4-fluorobenzyl -27 trifluoromethyphenyl 4-NH 2 3 3-fluorobenzyl 11-28 4-chlorophenyl 4-N(H)C(O)CH 3 3 3,4-dichlorobenzyl 11-29 3-chlorophenyl 4-N(H)C(O)-phenyl 3 3,4-difluorobenzyl 11-30 4-fluorophenyl 4-CF 3 3 4-trifluoromethylbenzyl [0100] Multiple methods for preparing compounds described herein are provided in the examples. Further synthetic methods for preparing various compounds are described herein by reference to Scheme 1 below. The synthetic scheme is provided for the purpose of illustrating 5 the invention, but not for limiting the scope or spirit of the invention. Starting materials can be obtained from commercial sources or be prepared based on procedures described in the literature. [0101] The synthetic route in Scheme 1 illustrates a general method for preparing cycloalkyl guanidine compounds. The method involves reacting an optionally substituted benzoylchloride 10 with potassium thiocyanate to form an acyl isothiocyanate intermediate. This acyl isothiocyanate intermediate is treated with a cycloalkyl amine compound (e.g., a cyclohexyl amine) to form an acyl thiourea. The acyl thiourea is reacted with 1-ethyl-2',2' dimethylaminopropylcarbodiimide (EDCI) and a second amine compound (e.g., an aniline or benzylamine) to form the desired cycloalkyl guanidine compound. To the extent either the 15 cycloalkyl amine compound or the second amine compound contain a further functional group that may undergo reaction under the conditions illustrated in Scheme 1, standard protecting group strategies for protection and deprotection may be employed. See, for example, Greene, T.W.; Wuts, P.G.M. Protective Groups in Organic Synthesis, 2 ed.; Wiley: New York, 1991.
WO 2012/078867 PCT/US2011/063943 - 32 SCHEME 1 Ci KSCN NCS RNH 2 N NR acetonitrile H H 0 EDCI,
R
1
-NH
2 RX N NH H R IV. Therapeutic Applications of Guanidine Compounds 5 [0102] It is contemplated that the guanidine compounds described herein, such as compounds of Formula I, Formula I-A, Formula I-A1, and related guanidine-based compounds, provide therapeutic benefits to patients suffering from any one or more of a number of conditions, e.g., diseases characterized by dysregulation of FiFo-ATPase activity, diseases characterized by dysregulation of necrosis and/or apoptosis processes in a cell or tissue, disease characterized by 10 aberrant cell growth and/or hyperproliferation. The compounds described herein can also be used to treat a variety of dysregulatory disorders related to cellular death as described elsewhere herein. Additionally, the compounds described herein can be used to inhibit ATP synthesis. [0103] A large number of diseases can be treated using the guanidine compounds described 15 herein. For example, the compounds described herein can be used to treat diseases characterized by dysregulation of necrosis and/or apoptosis processes in a cell or tissue, diseases characterized by aberrant cell growth and/or hyperproliferation, etc., or lupus, rheumatoid arthritis, psoriasis, graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, cardiovascular disease, myeloma, lymphoma, cancer, and bacterial 20 infection. In certain embodiments, the cancer is a solid tumor, leukemia, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, lung cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, stomach cancer, cervical cancer, testicular tumor, skin cancer, rectal cancer, thyroid cancer, kidney cancer, WO 2012/078867 PCT/US2011/063943 - 33 uterus cancer, espophagus cancer, liver cancer, an acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, or retinoblastoma. [0104] Although not wishing to be bound to a particular theory, it is believed that the compounds impart therapeutic benefit by modulating (e.g., inhibiting or promoting) the activity 5 of the FiFo-ATPase complexes (e.g., mitochondrial FiFo-ATPase complexes) in affected cells or tissues. In some embodiments, the compositions of the present invention are used to treat immune/chronic inflammatory conditions (e.g., psoriasis, autoimmune disorders, organ transplant rejection, and epidermal hyperplasia). In further embodiments, the compositions of the present invention are used in conjunction with stenosis therapy to treat compromised (e.g., 10 occluded) vessels. [0105] In certain embodiments, a composition comprising a guanidine compound is administered under conditions (e.g., timing, dose, co-administration with other agent, mode of administration, selection of subject, use of targeting agents, etc.) that maximize desired effects directed at the FiFo-ATPase. 15 [0106] In certain embodiments, the disorder is an immune disorder. In certain other embodiments, the disorder is an inflammatory disorder. In certain other embodiments, the disorder is an autoimmune disorder. In certain other embodiments, the disorder is rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac 20 Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, asthma, uveitis, or epidermal hyperplasia. [0107] In certain other embodiments, the disorder is cartilage inflammation, bone degradation, arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile 25 rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reter's Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive 30 arthritis, Reter's Syndrome, dermatomyositis, psoriatic arthritis, vasculitis, myolitis, polymyolitis, dermatomyolitis, osteoarthritis, polyarteritis nodossa, Wegener's granulomatosis, WO 2012/078867 PCT/US2011/063943 - 34 arteritis, polymyalgia rheumatica, sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, atherosclerosis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Type I diabetes mellitus, Graves' disease, Addison's disease, Raynaud's phenomenon, or autoimmune hepatitis. In certain embodiments, the 5 psoriasis is plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, or erythrodermic psoriasis. [0108] In certain other embodiments, the disorder is Crohn's disease, inflammatory bowel disease, multiple sclerosis, graft-versus-host disease, lupus, rheumatoid arthritis, or psoriasis. In certain other embodiments, the disorder is cardiovascular disease, myeloma, lymphoma, or 10 cancer. In certain other embodiments, the disorder is lupus, rheumatoid arthritis, psoriasis, graft-versus-host disease, myeloma, or lymphoma. In certain other embodiments, the disorder is cardiovascular disease or cancer. In certain other embodiments, the disorder is Crohn's disease, inflammatory bowel disease, or multiple sclerosis. In certain other embodiments, the disorder is graft-versus-host disease. In further embodiments, the disorder is a bacterial 15 infection. In certain embodiments, the patient is a human. [0109] As indicated above, the guanidine compounds described herein can be used in the treatment of a bacterial infection. A variety of bacteria are contemplated to be susceptible to the guanidine compounds. Representative bacteria include Staphylococci species, e.g., S. aureus; Enterococci species, e.g., E. faecalis and E. faecium; Streptococci species, e.g., S. 20 pyogenes and S. pneumoniae; Escherichia species, e.g., E. coli, including enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic and enteroaggregative E. coli strains; Haemophilus species, e.g., H. influenza; and Moraxella species, e.g., M. catarrhalis. Other examples include Mycobacteria species, e.g., M. tuberculosis, M. avian-intracellulare, M. kansasii, M. bovis, M. africanum, M. genavense, M. leprae, M. xenopi, M. simiae, M. 25 scrofulaceum, M. malmoense, M. celatum, M. abscessus, M. chelonae, M. szulgai, M. gordonae, M. haemophilum, M. fortuni and M. marinum; Corynebacteria species, e.g., C. diphtheriae; Vibrio species, e.g., V. cholerae; Campylobacter species, e.g., C. jejuni; Helicobacter species, e.g., H. pylori; Pseudomonas species, e.g., P. aeruginosa; Legionella species, e.g., L. pneumophila; Treponema species, e.g., T. pallidum; Borrelia species, e.g., B. 30 burgdorferi; Listeria species, e.g., L monocytogenes; Bacillus species, e.g., B. cereus; Bordatella species, e.g., B. pertussis; Clostridium species, e.g., C. perfringens, C. tetani, C. difficile and C. botulinum; Neisseria species, e.g., N. meningitidis and N. gonorrhoeae; WO 2012/078867 PCT/US2011/063943 - 35 Chlamydia species, e.g., C. psittaci, C. pneumoniae and C. trachomatis; Rickettsia species, e.g., R. rickettsii and R. prowazekii; Shigella species, e.g., S. sonnei; Salmonella species, e.g., S. typhimurium; Yersinia species, e.g., Y. enterocolitica and Y. pseudotuberculosis; Klebsiella species, e.g., K. pneumoniae; Mycoplasma species, e.g., M. pneumoniae; and Trypanosoma 5 brucei. In certain embodiments, the guanidine compounds described herein are used to treat a subject suffering from a bacterial infection selected from the group consisting of S. aureus, E. faecalis, E. faecium, S. pyogenes, S. pneumonia, and P. aeruginosa. In certain embodiments, the guanidine compounds described herein are used to treat a subject suffering from a Trypanosoma brucei infection. 10 [0110] The antibacterial activity of the compounds described herein may be evaluated using standard assays known in the art, such as the microbroth dilution minimum inhibition concentration (MIC) assay, as further described in National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement. NCCLS document M100-S14 {ISBN 1-56238-516-X}. This assay 15 may be used to determine the minimum concentration of a compound necessary to prevent visible bacterial growth in a solution. In general, the drug to be tested is serially diluted into wells, and aliquots of liquid bacterial culture are added. This mixture is incubated under appropriate conditions, and then tested for growth of the bacteria. Compounds with low or no antibiotic activity (a high MIC) will allow growth at high concentrations of compound, while 20 compounds with high antibiotic activity will allow bacterial growth only at lower concentrations (a low MIC). [0111] The assay uses stock bacterial culture conditions appropriate for the chosen strain of bacteria. Stock cultures from the permanent stock culture collection can be stored as frozen suspensions at -70'C. Cultures may be suspended in 10% skim milk (BD) prior to snap 25 freezing in dry ice/ethanol and then placed in a -70'C freezer. Cultures may be maintained on Tryptic Soy Agar containing 5% Sheep Blood at room temperature (20'C), and each culture may be recovered from frozen form and transferred an additional time before MIC testing. Fresh plates are inoculated the day before testing, incubated overnight, and checked to confirm purity and identity. 30 [0112] The identity and purity of the cultures recovered from the stock culture can be confirmed to rule out the possibility of contamination. The identity of the strains may be WO 2012/078867 PCT/US2011/063943 - 36 confirmed by standard microbiological methods (See, e.g., Murray et al., Manual of Clinical Microbiology, Eighth Edition. ASM Press {ISBN 1-55581-255-4}). In general, cultures are streaked onto appropriate agar plates for visualization of purity, expected colony morphology, and hemolytic patterns. Gram stains can also be utilized. The identities are confirmed using a 5 MicroScan WalkAway 40 SI Instrument (Dade Behring, West Sacramento, California). This device utilizes an automated incubator, reader, and computer to assess for identification purposes the biochemical reactions carried out by each organism. The MicroScan WalkAway can also be used to determine a preliminary MIC, which may be confirmed using the method described below. 10 [0113] Frozen stock cultures may be used as the initial source of organisms for performing microbroth dilution minimum inhibition concentration (MIC) testing. Stock cultures are passed on their standard growth medium for at least 1 growth cycle (18-24 hours) prior to their use. Most bacteria may be prepared directly from agar plates in 10 mL aliquots of the appropriate broth medium. Bacterial cultures are adjusted to the opacity of a 0.5 McFarland Standard 15 (optical density value of 0.28-0.33 on a Perkin-Elmer Lambda EZ150 Spectrophotometer, Wellesley, Massachusetts, set at a wavelength of 600nm). The adjusted cultures are then diluted 400 fold (0.25 mL inoculum + 100 mL broth) in growth media to produce a starting suspension of approximately 5 x 105 colony forming units (CFU)/mL. Most bacterial strains may be tested in cation adjusted Mueller Hinton Broth (CAMHB). 20 [0114] Test compounds ("drugs") are solubilized in a solvent suitable for the assay, such as DMSO. Drug stock solutions may be prepared on the day of testing. Microbroth dilution stock plates may be prepared in two dilution series, 64 to 0.06 [g drug/mL and 0.25 to 0.00025 pg drug/mL. For the high concentration series, 200 [L of stock solution (2 mg/mL) is added to duplicate rows of a 96-well microtiter plate. This is used as the first well in the dilution series. 25 Serial two-fold decremental dilutions are made using a BioMek FX robot (Beckman Coulter Inc., Fullerton, CA) with 10 of the remaining 11 wells, each of which will contain 100 [L of the appropriate solvent/diluent. Row 12 contains solvent/diluent only and serves as the control. For the first well of the low concentration series, 200 [L of an 8 [g/mL stock are added to duplicate rows of a 96-well plate. Serial two-fold dilutions are made as described above. 30 [0115] Daughter 96-well plates may be spotted (3.2 pL/well) from the stock plates listed above using the BioMek FX robot and used immediately or frozen at -70'C until use. Aerobic WO 2012/078867 PCT/US2011/063943 - 37 organisms are inoculated (100 [tL volumes) into the thawed plates using the BioMek FX robot. The inoculated plates are be placed in stacks and covered with an empty plate. These plates are then incubated for 16 to 24 hours in ambient atmosphere according to CLSI guidelines (National Committee for Clinical Laboratory Standards, Methods for Dilution, Antimicrobial 5 Tests for Bacteria that Grow Aerobically; Approved Standard-Sixth Edition. NCCLS document M7-A6 {ISBN 1-56238-486-41). [0116] After inoculation and incubation, the degree of bacterial growth can be estimated visually with the aid of a Test Reading Mirror (Dynex Technologies 220 16) in a darkened room with a single light shining directly through the top of the microbroth tray. The MIC is the 10 lowest concentration of drug that prevents macroscopically visible growth under the conditions of the test. [0117] In certain embodiments, the patient is a human. Combination Therapy [0118] Additionally, the guanidine compounds described herein can be used in combination 15 with at least one other therapeutic agent, such as Bz-423 (a benzodiazepine compound as described in U.S. Patent Nos. 7,144,880 and 7,125,866, U.S. Patent Application Serial Nos. 11/586,097, 11/585,492, 11/445,010, 11/324,419, 11/176,719, 11/110,228, 10/935,333, 10/886,450, 10/795,535, 10/634,114, 10/427, 211, 10/217,878, and 09/767,283, and U.S. Provisional Patent Nos. 60/878,519, 60/812,270, 60/802,394, 60/732,045, 60/730,711, 20 60/704,102, 60/686,348, 60/641,040, 60/607,599, and 60/565,788), potassium channel openers, calcium channel blockers, sodium hydrogen exchanger inhibitors, antiarrhythmic agents, antiatherosclerotic agents, anticoagulants, antithrombotic agents, prothrombolytic agents, fibrinogen antagonists, diuretics, antihypertensive agents, ATPase inhibitors, mineralocorticoid receptor antagonists, phospodiesterase inhibitors, antidiabetic agents, anti-inflammatory agents, 25 antioxidants, angiogenesis modulators, antiosteoporosis agents, hormone replacement therapies, hormone receptor modulators, oral contraceptives, antiobesity agents, antidepressants, antianxiety agents, antipsychotic agents, antiproliferative agents, antitumor agents, antiulcer and gastroesophageal reflux disease agents, growth hormone agents and/or growth hormone secretagogues, thyroid mimetics, anti-infective agents, antiviral agents, 30 antibacterial agents, antifungal agents, cholesterol/lipid lowering agents and lipid profile therapies, and agents that mimic ischemic preconditioning and/or myocardial stunning, WO 2012/078867 PCT/US2011/063943 - 38 antiatherosclerotic agents, anticoagulants, antithrombotic agents, antihypertensive agents, antidiabetic agents, and antihypertensive agents selected from ACE inhibitors, AT-I receptor antagonists, ET receptor antagonists, dual ET/AII receptor antagonists, vasopepsidase inhibitors, an antiplatelet agent selected from GPIIb/IIIa blockers, P2Yi and P2Y 12 antagonists, 5 thromboxane receptor antagonists, or aspirin, along with a pharmaceutically-acceptable carrier or diluent in a pharmaceutical composition. [0119] Additionally, any one or more of these compounds can be used to treat a FiFo-ATP hydrolase associated disorder (e.g., myocardial infarction, ventricular hypertrophy, coronary artery disease, non-Q wave MI, congestive heart failure, cardiac arrhythmias, unstable angina, 10 chronic stable angina, Prinzmetal's angina, high blood pressure, intermittent claudication, peripheral occlusive arterial disease, thrombotic or thromboembolic symptoms of thromboembolic stroke, venous thrombosis, arterial thrombosis, cerebral thrombosis, pulmonary embolism, cerebral embolism, thrombophilia, disseminated intravascular coagulation, restenosis, atrial fibrillation, ventricular enlargement, atherosclerotic vascular 15 disease, atherosclerotic plaque rupture, atherosclerotic plaque formation, transplant atherosclerosis, vascular remodeling atherosclerosis, cancer, surgery, inflammation, systematic infection, artificial surfaces, interventional cardiology, immobility, medication, pregnancy and fetal loss, and diabetic complications comprising retinopathy, nephropathy and neuropathy) in a patient. 20 V. Pharmaceutical Compositions, Formulations, and Exemplary Administration Routes and Dosing Considerations [0120] Exemplary embodiments of various contemplated medicaments and pharmaceutical compositions are provided below. A. Preparing Medicaments 25 [0121] The compounds of the present invention are useful in the preparation of medicaments to treat or study a variety of conditions associated with dysregulation of cell death, aberrant cell growth and hyperproliferation. [0122] In addition, the compounds are also useful for preparing medicaments for treating or studying other disorders wherein the effectiveness of the compounds are known or predicted. 30 Such disorders include, but are not limited to, neurological (e.g., epilepsy) or neuromuscular WO 2012/078867 PCT/US2011/063943 - 39 disorders. The methods and techniques for preparing medicaments of a compound of the present invention are well-known in the art. Exemplary pharmaceutical formulations and routes of delivery are described below. [0123] One of skill in the art will appreciate that any one or more of the compounds described 5 herein, including the many specific embodiments, are prepared by applying standard pharmaceutical manufacturing procedures. Such medicaments can be delivered to the subject by using delivery methods that are well-known in the pharmaceutical arts. B. Exemplary Pharmaceutical Compositions and Formulation [0124] In some embodiments of the present invention, the compositions are administered 10 alone, while in some other embodiments, the compositions are preferably present in a pharmaceutical formulation comprising at least one active ingredient/agent, as discussed above, together with a solid support or alternatively, together with one or more pharmaceutically acceptable carriers and optionally other therapeutic agents (e.g., those described in section IV hereinabove). Each carrier should be "acceptable" in the sense that it is compatible with the 15 other ingredients of the formulation and not injurious to the subject. [0125] Contemplated formulations include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and pulmonary administration. In some embodiments, formulations are conveniently presented in unit dosage form and are prepared by 20 any method known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association (e.g., mixing) the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product. 25 [0126] Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, wherein each preferably contains a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. In other embodiments, the active ingredient is presented as a 30 bolus, electuary, or paste, etc.
WO 2012/078867 PCT/US2011/063943 - 40 [0127] In some embodiments, tablets comprise at least one active ingredient and optionally one or more accessory agents/carriers are made by compressing or molding the respective agents. In some embodiments, compressed tablets are prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally 5 mixed with a binder (e.g., povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g., sodium starch glycolate, cross-linked povidone, cross linked sodium carboxymethyl cellulose) surface-active or dispersing agent. Molded tablets are made by molding in a suitable machine a mixture of the powdered compound (e.g., active ingredient) moistened with an inert liquid diluent. Tablets may optionally be coated or scored 10 and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach. [0128] Formulations suitable for topical administration in the mouth include lozenges 15 comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. [0129] Pharmaceutical compositions for topical administration according to the present 20 invention are optionally formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. In alternative embodiments, topical formulations comprise patches or dressings such as a bandage or adhesive plasters impregnated with active ingredient(s), and optionally one or more excipients or diluents. In some embodiments, the topical formulations include a compound(s) that enhances absorption or 25 penetration of the active agent(s) through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide (DMSO) and related analogues. [0130] If desired, the aqueous phase of a cream base includes, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and 30 mixtures thereof.
WO 2012/078867 PCT/US2011/063943 - 41 [0131] In some embodiments, oily phase emulsions of this invention are constituted from known ingredients in a known manner. This phase typically comprises a lone emulsifier (otherwise known as an emulgent), it is also desirable in some embodiments for this phase to further comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and 5 an oil. [0132] Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier so as to act as a stabilizer. In some embodiments it is also preferable to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and/or fat make up the so-called emulsifying ointment 10 base which forms the oily dispersed phase of the cream formulations. [0133] Emulgents and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate. [0134] The choice of suitable oils or fats for the formulation is based on achieving the desired 15 properties (e.g., cosmetic properties), since the solubility of the active compound/agent in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus creams should preferably be non-greasy, non-staining and washable products with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty 20 acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used. 25 [0135] Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the agent. [0136] Formulations for rectal administration may be presented as a suppository with suitable base comprising, for example, cocoa butter or a salicylate.
WO 2012/078867 PCT/US2011/063943 - 42 [0137] Formulations suitable for vaginal administration may be presented as pessaries, creams, gels, pastes, foams or spray formulations containing in addition to the agent, such carriers as are known in the art to be appropriate. [0138] Formulations suitable for nasal administration, wherein the carrier is a solid, include 5 coarse powders having a particle size, for example, in the range of about 20 to about 500 microns which are administered in the manner in which snuff is taken, i.e., by rapid inhalation (e.g., forced) through the nasal passage from a container of the powder held close up to the nose. Other suitable formulations wherein the carrier is a liquid for administration include, but are not limited to, nasal sprays, drops, or aerosols by nebulizer, and include aqueous or oily 10 solutions of the agents. [0139] Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and 15 thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. In some embodiments, the formulations are presented/formulated in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried lyophilizedd) condition requiring only the addition of the sterile liquid carrier, for example water for injections, 20 immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. [0140] Preferred unit dosage formulations are those containing a daily dose or unit, daily subdose, as herein above-recited, or an appropriate fraction thereof, of an agent. [0141] It should be understood that in addition to the ingredients particularly mentioned 25 above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents. It also is intended that the agents, compositions and methods of this invention be combined with other suitable compositions and therapies. Still other formulations optionally include food 30 additives (suitable sweeteners, flavorings, colorings, etc.), phytonutrients (e.g., flax seed oil), WO 2012/078867 PCT/US2011/063943 - 43 minerals (e.g., Ca, Fe, K, etc.), vitamins, and other acceptable compositions (e.g., conjugated linoelic acid), extenders, and stabilizers, etc. C. Exemplary Administration Routes and Dosing Considerations [0142] Various delivery systems are known and can be used to administer therapeutic agents 5 (e.g., exemplary compounds as described above) of the present invention, e.g., encapsulation in liposomes, microparticles, microcapsules, receptor-mediated endocytosis, and the like. Methods of delivery include, but are not limited to, intra-arterial, intra-muscular, intravenous, intranasal, and oral routes. In specific embodiments, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may 10 be achieved by, for example, and not by way of limitation, local infusion during surgery, injection, or by means of a catheter. [0143] The agents identified can be administered to subjects or individuals susceptible to or at risk of developing pathological growth of target cells and correlated conditions. When the agent is administered to a subject such as a mouse, a rat or a human patient, the agent can be 15 added to a pharmaceutically acceptable carrier and systemically or topically administered to the subject. To identify patients that can be beneficially treated, a tissue sample is removed from the patient and the cells are assayed for sensitivity to the agent. [0144] Therapeutic amounts are empirically determined and vary with the pathology being treated, the subject being treated and the efficacy and toxicity of the agent. When delivered to 20 an animal, the method is useful to further confirm efficacy of the agent. One example of an animal model is MLR/MpJ-lpr/lpr ("MLR-lpr") (available from Jackson Laboratories, Bar Harbor, Maine ). MLR-lpr mice develop systemic autoimmune disease. Alternatively, other animal models can be developed by inducing tumor growth, for example, by subcutaneously inoculating nude mice with about 105 to about 10 9 hyperproliferative, cancer or target cells as 25 defined herein. When the tumor is established, the compounds described herein are administered, for example, by subcutaneous injection around the tumor. Tumor measurements to determine reduction of tumor size are made in two dimensions using venier calipers twice a week. Other animal models may also be employed as appropriate. Such animal models for the above-described diseases and conditions are well-known in the art. 30 [0145] In some embodiments, in vivo administration is effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective WO 2012/078867 PCT/US2011/063943 - 44 means and dosage of administration are well known to those of skill in the art and vary with the composition used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations are carried out with the dose level and pattern being selected by the treating physician. 5 [0146] Suitable dosage formulations and methods of administering the agents are readily determined by those of skill in the art. Preferably, the compounds are administered at about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg. When the compounds described herein are co-administered with another agent (e.g., as sensitizing agents), the effective amount may 10 be less than when the agent is used alone. [0147] The pharmaceutical compositions can be administered orally, intranasally, parenterally or by inhalation therapy, and may take the form of tablets, lozenges, granules, capsules, pills, ampoules, suppositories or aerosol form. They may also take the form of suspensions, solutions and emulsions of the active ingredient in aqueous or non-aqueous diluents, syrups, 15 granulates or powders. In addition to an agent of the present invention, the pharmaceutical compositions can also contain other pharmaceutically active compounds or a plurality of compounds of the invention. [0148] More particularly, an agent of the present invention also referred to herein as the active ingredient, may be administered for therapy by any suitable route including, but not 20 limited to, oral, rectal, nasal, topical (including, but not limited to, transdermal, aerosol, buccal and sublingual), vaginal, parental (including, but not limited to, subcutaneous, intramuscular, intravenous and intradermal) and pulmonary. It is also appreciated that the preferred route varies with the condition and age of the recipient, and the disease being treated. [0149] Ideally, the agent should be administered to achieve peak concentrations of the active 25 compound at sites of disease. This may be achieved, for example, by the intravenous injection of the agent, optionally in saline, or by oral administration, for example, as a tablet, capsule or syrup containing the active ingredient. [0150] Desirable blood levels of the agent may be maintained by a continuous infusion to provide a therapeutic amount of the active ingredient within disease tissue. The use of 30 operative combinations is contemplated to provide therapeutic combinations requiring a lower WO 2012/078867 PCT/US2011/063943 - 45 total dosage of each component than may be required when each individual therapeutic compound or drug is used alone, thereby reducing adverse effects. D. Exemplary Co-administration Routes and Dosing Considerations [0151] The invention also includes methods involving co-administration of the compounds 5 described herein with one or more additional active agents. Indeed, it is a further aspect of this invention to provide methods for enhancing prior art therapies and/or pharmaceutical compositions by co-administering a compound of this invention. In co-administration procedures, the agents may be administered concurrently or sequentially. In one embodiment, the compounds described herein are administered prior to the other active agent(s). The 10 pharmaceutical formulations and modes of administration may be any of those described above. In addition, the two or more co-administered chemical agents, biological agents or radiation may each be administered using different modes or different formulations. [0152] The agent or agents to be co-administered depend on the type of condition being treated. For example, when the condition being treated is cancer, the additional agent can be a 15 chemotherapeutic agent or radiation. When the condition being treated is an immune disorder, the additional agent can be an immunosuppressant or an anti-inflammatory agent. When the condition being treated is chronic inflammation, the additional agent can be an anti inflammatory agent. The additional agents to be co-administered, such as anticancer, immunosuppressant, anti-inflammatory, can be any of the well-known agents in the art, 20 including, but not limited to, those that are currently in clinical use. The determination of appropriate type and dosage of radiation treatment is also within the skill in the art or can be determined with relative ease. [0153] Treatment of the various conditions associated with abnormal apoptosis is generally limited by the following two major factors: (1) the development of drug resistance and (2) the 25 toxicity of known therapeutic agents. In certain cancers, for example, resistance to chemicals and radiation therapy has been shown to be associated with inhibition of apoptosis. Some therapeutic agents have deleterious side effects, including non-specific lymphotoxicity, renal and bone marrow toxicity. [0154] The methods described herein address both these problems. Drug resistance, where 30 increasing dosages are required to achieve therapeutic benefit, is overcome by co-administering the compounds described herein with the known agent. The compounds described herein WO 2012/078867 PCT/US2011/063943 - 46 sensitize target cells to known agents (and vice versa) and, accordingly, less of these agents are needed to achieve a therapeutic benefit. [0155] The sensitizing function of the claimed compounds also addresses the problems associated with toxic effects of known therapeutics. In instances where the known agent is 5 toxic, it is desirable to limit the dosages administered in all cases, and particularly in those cases where drug resistance has increased the requisite dosage. When the claimed compounds are co-administered with the known agent, they reduce the dosage required which, in turn, reduces the deleterious effects. EXAMPLES [0156] The invention now being generally described, will be more readily understood by 10 reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention. EXAMPLE 1 - PREPARATION OF CYCLOALKYL GUANIDINE COMPOUNDS [0157] Cycloalkyl guanidine compounds can be prepared according to the general procedures 15 described below. Method A below provides a first general procedure for making cycloalkyl guanidine compounds. Methods B and C provide two alternative procedures that also can be used to prepare cycloalkyl guanidine compounds. Method A: SCHEME 1 0 0 0 S CI KSCN NCS RNH 2 NNR 0 I, acetonitrile 0 EDCI, R 1
-NH
2 R N NH 20 H R [0158] Guanidines can be prepared from an acid chloride, a first amine, and a second amine using a three-step procedure. First, the requisite acid chloride is combined with potassium WO 2012/078867 PCT/US2011/063943 - 47 thiocyanate in an organic solvent, and this mixture is stirred at ambient temperature for 1-4 hours. The resulting mixture is concentrated in vacuo and used immediately. [0159] In a second step, an appropriate first amine (RNH 2 ) is dissolved in an organic solvent, such as methylene chloride, at ambient temperature and the acyl isothiocyanate from the first 5 step is added. The resulting mixture is stirred at ambient temperature for 8-16 hours. The solvents are evaporated in vacuo and the resulting residue treated with a warm non-polar organic solvent, then allowed to cool and collected by filtration. The collected residue is rinsed with a non-polar organic solvent and dried. The resulting residue can be used without further purification. Alternatively, the first amine in the form of a hydrochloride salt is dissolved in an 10 organic solvent and treated with a hindered organic base such as triethylamine then stirred at ambient temperature for 1-4 hours. The acyl isothiocyanate from step 1 is then added and the reaction mixture stirred at ambient temperature for 8-16 hours. The solvents are removed in vacuo and the resulting residue is purified by chromatography. [0160] In the third step, the acyl thiourea from step 2 and an appropriate second amine (R 15 NH 2 ) are dissolved in a polar organic solvent such as dimethylformamide at ambient temperature to form a mixture. To this mixture, 1-ethyl-2',2' dimethylaminopropylcarbodiimide is added and the resulting mixture is stirred until the reaction appears complete by HPLC analysis of aliquots of the reaction mixture. Typical reaction times range from 30 minutes to 12 hours, and the reaction mixture may be heated (e.g., 20 to approximately 60 0 C) to accelerate the reaction. Once the reaction appears to be complete by HPLC analysis, the reaction mixture is diluted with an organic solvent (such as ethylacetate), washed with water, washed with brine, and the organic layer is dried over an appropriate drying agent, filtered, and the solvents removed under reduced pressure. The desired product can be purified by chromatography if necessary. 25 Representative Procedure for Preparation of an Acyl Thiourea. [0161] To a solution of 3,4-difluorobenzoylchloride (14.9 g, 85 mmol) in acetonitrile (160 ml) at 0 0 C was added potassium thiocyanate (8.6 g, 89 mmol) with stirring. After 10 minutes the cooling bath was removed and the mixture was stirred at room temperature for 1 h. The mixture was filtered and the filtrate was concentrated then redissolved in toluene (10 mL). This 30 solution was added to a solution of ethyl (4-aminocyclohexyl)carbamate in toluene (79 mL) at room temperature. The resulting suspension was stirred at room temperature for 30 minutes, WO 2012/078867 PCT/US2011/063943 - 48 then filtered, and the pad was rinsed with toluene (10 mL) and dried to give ethyl ((1r,4r)-4-(3 (3,4-difluorobenzoyl)thioureido)cyclohexyl)carbamate as a white solid (28.2 g, 9 1%). Representative Procedure for Coupling of an Acyl Thiourea to an Amine. [0162] Ethyl ((1r,4r)-4-(3-(3,4-difluorobenzoyl)thioureido)cyclohexyl)carbamate (100 mg, 5 0.26 mmol) and cyclopentanamine (66 mg, 0.778 mmol) were combined in dry dimethylformamide (1.5 mL) and Ni -((ethylimino)methylene)-N3,N3-dimethylpropane- 1,3 diamine (48 mg, 0.31 mmol) was added. The mixture was heated to 65 0 C for 1.5 h then allowed to cool and diluted with ethyl acetate. This solution was washed with water, then saturated ammonium chloride (aqueous) followed by brine. The product was purified by 10 chromatography (10-50% ethyl acetate in hexanes) to give ethyl ((lr,4r)-4-((Z)-3-cyclopentyl 2-(3,4-difluorobenzoyl)guanidino)cyclohexyl)carbamate (86 mg, 76%). Method B: SCHEME 2 o O oO s CI KSCN NCS RNH 2 N N'R Acetone 0 Bil 3 , NaBiO 3 1 R Et 3 N, ACN N NH
R
1
-NH
2 H R 15 [0163] A aliquot of potassium thiocyanate (6.6 mmol, 1.1 eq) is added in one portion to a stirred solution of acyl chloride (6 mmol, 1 eq) in acetonitrile (20 mL) cooled in an ice bath. After 10 min, the ice bath is removed and the reaction mixture is allowed to stir at ambient temperature. After 6 h, the amine (6.6 mmol, 1.1 eq) is added, and the mixture is stirred at ambient temperature. Reaction progress can be monitored by analyzing a sample of the 20 reaction mixture by HPLC. Once the reaction is sufficiently complete, the reaction mixture is concentrated in vacuo, and the residue partitioned between water (50 mL) and ethyl acetate (50 mL). The organic later is separated from the aqueous layer, and then the aqueous layer is extracted with ethyl acetate (25 mL). The organic layers are combined, dried over anhydrous Na 2
SO
4 , and concentrated in vacuo to give the thiourea.
WO 2012/078867 PCT/US2011/063943 - 49 [0164] To a stirred solution of the thiourea (0.06 mmol, 1 eq) and triethylamine (0.12 mmol, 2 eq) in acetonitrile (0.5 mL) in a vial are added sodium bismuthate (0.06 mmol, 1 eq), bismuth (III) iodide (0.003 mmol, 0.05 eq), and the amine compound corresponding to RINH 2 . The vial is capped and heated (e.g., heated to 65'C) with stirring. The progress of the reaction may be 5 monitored by analyzing a sample of the reaction mixture using HPLC. Once the reaction is sufficiently complete, the reaction mixture is cooled, diluted with water, extracted with ethyl acetate and the organic layer is washed with brine, dried over an appropriate drying agent (e.g., MgSO 4 ), filtered, and the solvents removed under reduced pressure. The desired product can be purified by chromatography if necessary. 10 [0165] Additional procedures for the synthesis of substituted guanidine compounds are described in S. Cunha et al. Tetrahedron Letters 47 (2006) 6955 and S. Cunha et al. Tetrahedron Letters 43 (2002) 49-52, each of which is hereby incorporated by reference. Method C: SCHEME 3 0 S CI KSCN NCS RNH 2 ,0R acetonitrile 0 EDCI, R 1
-NH
2 , R N I X N NH Y IH 15 H R [0166] Acyl guanidines can be prepared from an acid chloride, a first amine, and a second amine using a three-step, 2-pot procedure. First, the requisite acid chloride is combined with a slight molar excess of potassium thiocyanate in a polar aprotic solvent (such as acetonitrile) at a temperature in the range of from about 0 0 C to room temperature. The resulting mixture is 20 stirred for a time period ranging from 15 minutes to 2 hours to provide a reaction mixture containing the acyl isothiocyanate synthetic intermediate compound. This reaction mixture may be used directly in the next reaction or filtered to remove the potassium chloride generated during this first step. [0167] In a second step, the acyl isothiocyanate compound is combined with a second amine 25 (which may be dissolved in a solvent) to provide a reaction mixture that is stirred for a time WO 2012/078867 PCT/US2011/063943 - 50 period ranging from 15 minutes to 2 hours to produce an acyl thiourea product. The acyl thiourea product often precipitates from the reaction mixture and may be collected by filtration. Water may be added to the reaction mixture (typically in amount equal to the volume of organic solvent) to facilitate collection of the acyl thiourea product. The acyl thiourea product 5 is dried in vacuo at approximately ambient temperature. [0168] In a third step, the acyl thiourea product is combined with a coupling agent (such as N (3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDCI)) and a second amine to produce the acyl guanidine. All starting materials for this reaction may be combined prior to heating the reaction mixture or the EDCI may be added last, once the temperature of the reaction mixture 10 has been raised. Alternatively, the second amine may be added last after combining the thiourea and the EDCI. Once all the starting materials have been combined, the reaction mixture is generally stirred for a time period ranging from about 30 minutes to about 3 hours while the reaction mixture is heated to a temperature ranging from about 45 0 C to about 70 0 C. Representative Procedure for Preparing Ethyl ((lr,4r)-4-(3-(3-chloro-5-fluorophenyl)-2-(4 15 fluoro-3-(methylsulfonyl)benzoyl)guanidino)cyclohexyl)carbamate Using Method C Step A: Preparation of Preparation of Ethyl ((1r,4r)-4-(3-(3,4-difluorobenzoyl) thioureido)cyclohexyl)carbamate 0 S NHCO2Et 0 0 S F C 1 KSCN F N 2. e H H F H 2 N'"* '3 NHCO 2 Et F [0169] To a solution of 3,4-difluorobenzoyl chloride (14.93 g, 85 mmol, 1.05 equiv) in 20 acetonitrile at 0 0 C was added potassium thiocyanate (8.6 g, 89 mmol, 1.1 equiv). This mixture was stirred for 10 minutes at 0 0 C then the cooling bath was removed and the mixture was stirred at RT for 1 hr. Next, the reaction mixture was filtered to removed KCl. Then, the filtrate was concentrated and redissolved in toluene (10 mL). This solution was added to a solution of ethyl (trans-4-aminocyclohexyl)carbamate in toluene (80 mL) at RT with stirring. 25 The resulting suspension was stirred for 30 minutes, then filtered and rinsed with toluene (10 mL). The resulting pad was dried in vacuo to provide the title compound.
WO 2012/078867 PCT/US2011/063943 - 51 Step B: Preparation of Ethyl ((1r,4r)-4-(3-(3-chloro-5-fluorophenyl)-2-(3,4 difluorobenzoyl)guanidino)cyclohexyl)carbamate F F F 0 S ., NHCO 2 Et H 2 N F F N N1 CI 0 N H H EDCI HN N CI F H
NHCO
2 Et [0170] Ethyl ((1r,4r)-4-(3-(3,4-difluorobenzoyl)thioureido) cyclohexyl)carbamate (28.2 g, 5 73.2 mmol) was suspended in acetonitrile ( 244 mL) and 3-chloro-5-fluoroaniline (10 .65 g, 73.2 mmol) was added. The resulting mixture was warmed to 65 0 C under nitrogen. EDCI (21.04 g, 110 mmol) was added to the reaction mixture, and the resulting mixture was stirred for 1 hr then allowed to cool to room temperature (RT) and filtered. The filtrate was warmed to 60 0 C and diluted with water (244 mL). The resulting suspension was stirred at 60 0 C for 30 10 minutes, and then at RT for 2 hr. The solid was collected by filtration and rinsed with 1:1 acetonitrile:water, then dried at 60 0 C under vacuum to provide the title compound, which was purified by crystallization from ethanol. Representative Procedure for Preparing Ethyl ((lr,4r)-4-(3-(3-chloro-5-fluorophenyl)-2-(4 fluoro-3-(methylsulfonyl)benzoyl)guanidino)cyclohexyl)carbamate Using Method C 15 Step A: Preparation of Ethyl ((1r,4r)-4-(3-(4-fluoro-3 (methylsulfonyl)benzoyl)thioureido) cyclohexyl) carbamate H 1. KSCN 0 O CI 2. H N kN F I N,- 0FH H
H
2 N [0171] The title compound was prepared from 4-fluoro-3-(methylsulfonyl)benzoyl chloride, potassium thiocyanate, and ethyl (1r,4r)-4-aminocyclohexylcarbamate based on synthetic 20 procedures described above.
WO 2012/078867 PCT/US2011/063943 - 52 Step B: Preparation of Ethyl ((1r,4r)-4-(3-(3-chloro-5-fluorophenyl)-2-(4-fluoro-3 (methylsulfonyl)benzoyl)guanidino)cyclohexyl)carbamate O F F / H H 2 N F H H EDCI CH N CI
NHCO
2 Et [0172] Ethyl ((1r,4r)-4-(3-(4-fluoro-3-(methylsulfonyl)benzoyl)thioureido)cyclohexyl) 5 carbamate (200 mg, 0.449 mmol), EDCI (95 mg, 0.49 mmol) and 3-chloro-5-fluoroaniline (85 mg, 0.58 mmol) were suspended in THF (5 ml) and heated to 50 0 C for 30 minutes. The crude mixture was concentrated onto silica gel and the crude product was purified by chromatography eluting with ethyl acetate in hexanes to provide the title compound. EXAMPLE 2 - REPRESENTATIVE PROCEDURE FOR OPTIONAL DERIVATIZATION OF AMINO 10 CYCLOALKYL GUANIDINE COMPOUNDS BY NUCLEOPHILIc AROMATIC SUBSTITUTION N N R NX Ar-CI R 1 , N I N H heat N H H H bt NH 2 NAr H [0173] Amino-cycloalkyl guanidine compounds prepared based on synthetic procedures described in Example 1 above can optionally be derivatized using nucleophilic aromatic substitution conditions. For example, reaction of an amino-cycloalkyl guanidine compound 15 with an aryl chloride or heteroaryl chloride provides the aryl or heteroaryl substituted compound, respectively. [0174] Exemplary Synthetic Procedure: The following exemplary synthetic procedure illustrates synthesis of (E)-N-((3-chloro-5-fluorophenylamino)(4-(pyrimidin-2 ylamino)cyclohexylamino)methylene)-3,4-difluorobenzamide starting from (E)-N-((((1r,4r)-4 20 aminocyclohexyl)amino)((3-chloro-5-fluorophenyl)amino)methylene)-3,4-difluorobenzamide.
WO 2012/078867 PCT/US2011/063943 - 53 In a microwave tube was combined the (E)-N-((((lr,4r)-4-aminocyclohexyl)amino)((3-chloro 5-fluorophenyl)amino)methylene)-3,4-difluorobenzamide (1.4 mmol, 1 eq) in N,N dimethylformamide (5 mL), diisopropylethylamine (2.8 mmol, 2 eq), and 2-chloropyrimidine (2.1 mmol, 1.5 eq). The reaction mixture was heated to 130'C for 20 minutes by microwave 5 (CEM Explorer). Then, the solution was cooled, and the cooled solution was diluted with ethyl acetate (30 mL), washed with water (3 x 25 mL), then brine, dried with sodium sulfate, filtered and concentrated in vacuo to provide the crude product. The crude product was purified by chromatography on silica gel eluting with a gradient of ethyl acetate in hexanes to provide (E) N-((3-chloro-5-fluorophenylamino)(4-(pyrimidin-2-ylamino)cyclohexylamino)methylene)-3,4 10 difluorobenzamide in purified form. EXAMPLE 3 - REPRESENTATIVE PROCEDURE FOR OPTIONAL DERIVATIZATION OF AMINO CYCLOALKYL GUANIDINE COMPOUNDS BY ACYLATION 0 0 R X CI R" R R H H
NH
2 N H R" is, for example, alkyl, aryl, or aralkyl [0175] Amino-cycloalkyl guanidine compounds prepared based on synthetic procedures 15 described in Example 1 above can optionally be derivatized by acylation of an amino group. For example, reaction of an amino-cycloalkyl guanidine compound with an acyl chloride provides the corresponding amide derivative. [0176] Exemplary Synthetic Procedure: The following exemplary synthetic procedure describes an exemplary acylation procedure: To (E)-N-((((lr,4r)-4 20 aminocyclohexyl)amino)((3-chloro-5-fluorophenyl)amino)methylene)-3,4-difluorobenzamide (0.12 mmol, 1 eq) in dichloromethane (1 mL) is added triethylamine (0.36 mmol, 3 eq) followed by an acyl chloride (0.12 mmol, 1 eq). This mixture is stirred at ambient temperature for 30 minutes. The solution is concentrated in vacuo and the resulting residue is redissolved in ethyl acetate (20 mL), washed with water, then brine, dried with sodium sulfate, filtered and 25 concentrated in vacuo. The product is purified by chromatography on silica gel eluting with a gradient of ethyl acetate in hexanes to provide the acylated product.
WO 2012/078867 PCT/US2011/063943 - 54 EXAMPLE 4 - ADDITIONAL CYCLOALKYL GUANIDINE COMPOUNDS & CHARACTERIZATION DATA [0177] Compounds in Table 3 below were prepared based on the above representative procedures. Starting materials can be obtained from commercial sources (e.g., acid chloride: 5 4-chlorobenzoyl chloride, 3-chlorobenzoyl chloride, and 4-fluorobenzoyl chloride; first amine compound: cyclohexane-1,4-diamine, tert-butyl (4-aminocyclohexyl)carbamate, 4 aminocyclohexanol, 2-aminocyclohexanol, and 4-aminocyclohexanecarboxylic acid; second amine: 2-trifluoromethylaniline and 2-tert-butylaniline) or readily prepared from commercially available materials. Furthermore, exemplary compounds were characterized by high 10 performance liquid chromatography (HPLC), mass spectrometry (MS) and/or H nuclear magnetic resonance spectroscopy. The HPLC method and retention time, along with mass spectral data are provided in Table 3 below. HPLC methods used are as follows: Method A conditions were Waters C-18 column, 4.6 x 150 mm, 3.5 micron, 23 0 C, 1.0 mL/min, 1 min 25% MeCN in H 2 0 (0.1% TFA), 10 min gradient of 25%-95% MeCN in H 2 0 (0.1% TFA), 15 95% MeCN in H 2 0 (0.1% TFA) for 5 min, and then equilibration to 25% MeCN in H 2 0 (0.1% TFA) over 2.0 min; Method B conditions were Agilent Zorbax C-18 column, 4.6 x 50 mm, 1.8 micron, 23 0 C, 1.0 mL/min, 1 min 25% MeCN in H 2 0 (0.1% TFA), 5 min gradient of 25%-95% MeCN in H 2 0 (0.1% TFA), 1 min at 95% MeCN in H 2 0 (0.1% TFA), and then equilibration to 25% MeCN in H 2 0 (0.1% TFA) over 1.0 min; Method C conditions were Phenomenex Kinetex 20 C18 (3.0 mm x 50 mm), 2.6 micron, 58 0 C, 1.5 mL/min, 4 min gradient 5% MeCN (0.1% TFA) in H 2 0 (0.1% TFA) to 100% MeCN (0.1%TFA), 100% MeCN (0.1% TFA) for 0.5 min, and then equilibration to 5% MeCN (0.1% TFA) in H 2 0 (0.1% TFA) over 1.5 min; and Method D conditions were Phenomenex Kinetex C18 (3.0 mm x 50 mm), 2.6 micron, 40 0 C, 1.5 mL/min, 4 min gradient 5% MeCN (0.1% TFA) in H 2 0 (0.1% TFA) to 100% MeCN (0.1%TFA), 100% 25 MeCN (0.1% TFA) for 0.5 min, and then equilibration to 5% MeCN (0.1% TFA) in H 2 0 (0.1% TFA) over 1.5 min. The phrase "MeCN (0.1% TFA)" is art-recognized and refers to acetonitrile containing 0.1% wt/wt trifluoroacetic acid. [0178] H nuclear magnetic resonance data for exemplary compounds is provided in Table 4.
WO 2012/078867 PCT/US2011/063943 - 55 TABLE 3' Compound MIW MIS (EI+) HPLc ReteIlC Com Chemical Structure (Rm1I) n1/z Method Rt nin Fime (min) F F H 461.52 460.4* A 9.01 N N SNH HO F F NH 2NH ,OH 473.41 472.17* A 8.38 N F N H F'' F 3 0 'NH -- F 518.5 517.15* A 8.45 4 N N 441.39 440.05* A 7.77 F N F A~ N N F H
FF
WO 2012/078867 PCT/US2011/063943 - 56 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention Lmz'h ime (min) 5 0NC 407.84 406.05, A 6.97 F N408.07 N H H O '* *' F 6 FN N CI1 425.83 46.04' A 8.42 NH oF 7 F 457.85 456.05' A 9.08 N N CI 458.06 F H F HOO 8 Nt 439.86 438.07 A 7.6 N N CI 440.06 F ~' H F
F
WO 2012/078867 PCT/US2011/063943 - 57 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (E tho Retention 'lne (mi n) CI H 9 F NN 502.92 ' A 7.95 NNI'll N d 504.97 H F F H 10 0 NH N 01-N 0* 496.91 495.04 A 9.93 F ~N N~e F H H F
-
0H 11N- N CI 482.88 482.95, A 9.42 I 484.95 H F F - 0 H 12 42.5 426.92 NH 42.9,q 63 H, N C
F
WO 2012/078867 PCT/US2011/063943 - 58 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention Time (min)
H
2 N 13 N N F 440.41 441.07 A 6.15 O H F F F F F O F F 0H FF 14 F 512.47 511.12* A 9.13 0A N H H F H F F 15 N N F 498.45 497.13* A 8.7 O N 0-1 H 16 455.42 455.99 A 7.59 Nj- N" b HI 0~ii WO 2012/078867 PCT/US2011/063943 - 59 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (E tho Retention No. 'lne (mi n) 17 HN'O CF 487.44 488.01 A 8.1 N4 N I HI
F
3 0 F F F" O H 18 N N,,, O 510.94 510.98, A 8.94 ~< r~9512.94 NH >N O H CI CI H O N N O789 19 N 478.98, A 8.67 19 F N N N"K>489 480.94 H F 9H0NH 20 0 484.93 486.9 A 6.95 FN 486.95l F
H
WO 2012/078867 PCT/US2011/063943 - 60 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention 'lne (mi n) HO' 21 N N 445.48 446.04 A 7.16 F F HO~NH 22I.. 412.01, 22 O 0 411.92 414.01 A 6.39 C.0N HO H 23 O N 413.46 414.04 A 6.58 F N H H 24 HO,,. NH 439.86 439.95' A 7.7 C 441.93 :11N~ N41 F C ' A H 1-F F HO,,, 25 HNH 406.13 405.94, A 6.95 N N CI C I "'O A H WO 2012/078867 PCT/US2011/063943 - 61 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure M1lW MS (EI+) HPLC Retention No. (g/mol) m/z Method 'ime (min) H O,. 26 a NH 424.3 423.90, A 8.43 ol 0 -Nc 425.91 N N CI H CI 27 NH OH 406.31 405.94 A 6.65 NNK 407.95 H CI F 28 CI NH NC ,OH 424.3 423.94 A 7.97 H 'N 0 CI. ClAj 0H OH 29 NH NOH 439.86 4.93' A 7.4 F F F F F 30 F NH N OH 473.41 473.97 A 8.42 F H F 0 WO 2012/078867 PCT/US2011/063943 - 62 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure M1lW MS (EI+) HPLC Retention No. (g/mol) m/z Method 'ime (min) YOH 31 O HN 421.87 422 D 1.95 Fe N NN~ F CI 32 0 455.42 456 D 2.04 S N Nr---b V H O 33 0 HN , F F 455.42 456 D 2.04 F N N- - F F H 34 O HN 455.42 456 D 2.06 F ~ N lN
-
F HO F F 35 O HN' 405.41 406 D 1.82 F ~ N N"' F< OH 36 0 HN' 405.41 406 D 1.88 F : NN .. N F I H
F
WO 2012/078867 PCT/US2011/063943 - 63 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention No. 'lne (min) <OH 37 O HN' OH 405.41 406 D 1.87 N F NAN N H O F F 38 O HN* O 423.4 424 D 1.87 F H I~ FN F HOH 39 o HN*'K 423.4 424 D 1.94 F F OH 40 0 HN ' F 423.4 424 D 1.88 FN F <OH 41 O HN "' 423.4 424 D 1.89 F A ~ 0N FN H 42 F NAN F 423.4 424 D 1.92 F H
F
WO 2012/078867 PCT/US2011/063943 - 64 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention No. 'lne (min) YOH 43 0 HN 439.9 440 D 1.96 F~N C F <OH 44 O HN 439.9 440 D 2.01 N ' N CI H O F F 45 0 HN 439.9 440 D 2.01 F N N F H O F cI1 46 0 HN'K > 439.9 440 D 2 F N NC F HF )::CI H N 47 0 HN, 0 492.95 493 D 2.18 N N H H F C H N O 48 0 HN 0 492.95 493 D 2.23 F O N'NN :.. cI IH I'a F
Z-
WO 2012/078867 PCT/US2011/063943 - 65 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention M ime (min) H N 49 0 HN O 492.95 493 D 2.24 Fe N~ NN . , I H F CI H N 50 0 HN 526.5 527 D 2.34 F N Ili" N FN F;o F H N 51 0 HN O F 526.5 527 D 2.31 NN F O H O F:] ~~ O l, H FF F F F 52 F N, O N e 526.5 527 D 2.34 0N N H H 53 0 HNo' 0 476.49 477 D 2.11 F H I WO 2012/078867 PCT/US2011/063943 - 66 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention 'lne (min) H N 54 0 HN O 476.49 477 D 2.14 F : N NN ~ F I H F F H N 55 0 HN, 0 494.48 495 D 2.17 F:0 N NN~ F F H I~ NF H N O 56 0 HN, 0 494.48 495 D 21.9 F ):)AN N F H H F F H N O 57 0 HN F 494.48 495 D 2.18 F N NAN -,& F I H F H 58 0 H NoC:: 0 494.48 495 D 2.17 F:, N NN ". F HFa F WO 2012/078867 PCT/US2011/063943 - 67 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention 'lne (mi n) H N 0 HN N 59 F e N "N F 494.48 495 D 2.22 F H F F H N 60 0 HN,- 0 510.94 511 D 2.25 F : , N N N " F H C Ia FN C F H N O 61 0 HN 510.94 511 D 2.28 F N iN 5. F I H ZI H N 62 O HN 510.94 511 D 2.3 FN iN H N O 63 O HN 510.94 511 D 2.29 F N N I~ HI) c WO 2012/078867 PCT/US2011/063943 - 68 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention 'Mlt e (min) F F H 0 64 N N -S-OH 553.95 NA NA NA 11 F NH "'OH O CI 65 N N C 457.85 NA NA NA F F F F H N,.. N 66 0 N 484.54 485.05 A 8.08 H ~N N~ H 67 N I'lN N / 490.55 491.06 A 6.48 H F H1_"
F
WO 2012/078867 PCT/US2011/063943 - 69 Compund IW NS (E+) HI-CHPLC Compound Chemical Structure M1lW MS (EI+) HPLC Retention No. (g/mol) m/z Method 'ime (min) F F F 0H 0 68 N O -- OH 457.85 A 7.96 C' < T i S-OH F F FF CF NH O 70 69 N H 457.85 8 A 8.4 -11O 459.94 NF CI H FN N 72 O HN356.95 5371 D 2.11 H F F CI d NH 0H 710o )*483 437.-88, A6. 71~ N 43.2 439.84 A 64 H c I H 72 0 HN NIIIIJ 516.95 517 D 2.11 F NANiW F IO H K~ c WO 2012/078867 PCT/US2011/063943 - 70 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (E tho Retention 'lte (min) H N TiN 73 0 HN,- N / 516.95 517 D 2.07 F NA V^ IH F C F H e'N N 74 0 HN N 516.95 517 D 2.1 F N Ii"N 17 ci I H I N F H -- N N N 75 0 HN 516.95 517 D 2.13 F NAIi"N F F I H K F HI F N N 76 0 450.5 451 B 4.58 ON H H F FO H 77 N-.. N 464.6 465.1 B 4.72 N H N 0 ^Ta
H
WO 2012/078867 PCT/US2011/063943 - 71 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention M ime (min) F
-
0 F H 78 N N 506.97 508.96 A 9.57 y H CI CI 79 NH NH2 406.86 NA A 5.35 N 0 F H F F 0 F H 80 NN 0 491.5 492 B 7.12 N NH o H H F F H 496.91, 81 N,. N 496.91 49.3 A 8.82 cI NHJk F'
H
WO 2012/078867 PCT/US2011/063943 - 72 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention 'lne (mi n) F
-
0 F H 82 N N 0 496.91 498.93 A 9.33 NH .. "'N O H F CI CI FNN H 83 N r N 502.92 528, A 7.08 iN~K) N .- 504.91 H FH F CI F H NH N N CI289 84 502.92 5689 A 7.28 IN F N N 504.91 F H F F F H 85 No 496.91 496.*91, A 10.33 ~NH F498.93 0 F
H
WO 2012/078867 PCT/US2011/063943 - 73 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (E tho Retention M ime (min) H 86 0 470.6 471.1 B 4.16 F N N H N N~N N H 87 N 456.5 457 B 3.83 F ~ N N F H NN 88 N 483.94 483.92, A 6.35 N N CI485.89 F ~ N N N CI F 0 H80 N H 89 0 j 1480.9 480.9 B 5.2 F )C
NH
WO 2012/078867 PCT/US2011/063943 - 74 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention Time (min) H 90 0 HN 499 498.9 B 4.14 F N N C H F c N H 91 0 HN 499 498.9 B 4.25 F N CI H F FCC H 92 O F 532.5 533 B 4.56 H N F FV F 3 0 H N N ,N 93 0 F 532.5 533 B 4.46 F F N NF F I
H
WO 2012/078867 PCT/US2011/063943 - 75 Compund IW NS (E+) HI-CHPLC Compound Chemical Structure M1lW MS (EI+) HPLC Retention No. (g/mol) m/z Method 'ime (min) F F F H 95 O 518.5 519 B 4.63 1N NH H F N N FF F H 97 F N N O 484.95 484. B 7.88 HN 0 oNo F,, 529 528 B 93 F N NuX N FH 98 NH N O 502.45 50.8 B 7.88 N N H F 98H 0 N NN H
F
WO 2012/078867 PCT/US2011/063943 - 76 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention 'lne (min) F 0 99 N OH 453.8 451.9 B 5.35 FH F H 100 F 466.88 466.87, A 8.01 N H 468.82 N C H H 101 0 NH 492.92 494.84 A 8.88 F 0~ N N 448 N N F H CI 102 0 0 NH 508.96 50.89 A 9.63 F N Nb " 108 N F H N O 103 O HN'0 424.48 424.99 B 7 F N j NH WO 2012/078867 PCT/US2011/063943 - 77 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention 'lne (min) F FO H 104 NN N, 408.44 408.93 B 6.01 NHN oANH F H 105 F>4>"N < NH 478.46 478.95 B 10.23 N60 F F H F ~ N N 106 0 HN 436.5 437 B 6.96 N O H H N 107 0 HN O 450.4 450.95 B 9.13 F] AN N F F H F O 0 HN ea 108 F 353.4 354 B 5.57
F:O
WO 2012/078867 PCT/US2011/063943 - 78 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention M ime (min) F F 0H FO H 109 N , N 436.5 436.97 B 6.73 NH <5 H F F NH 1120 N N 468.51 46.9 B 7.22 (5 H H ,N Ny 0HN N0 1 N N 465.5 456.97 B 7.6 F -s H F F H 0OHN i l 112 N H462.5 462.96 B 6.15 F F HNIO N N 113 ' XLN> 474.52 474.98 B 6.11 F H F-'
F
WO 2012/078867 PCT/US2011/063943 - 79 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure M1lW MS (EI+) HPLC Retention No. (g/mol) m/z Method 'ime (min) F F F O H 114 N N N 474.52 474.99 B 5.9 a NH N ilN' H F FF F H 1 N NH 117 N NN 1 CIN 524.94 535 B 5.15 H F F F NH K> N 116 JN 550.5 551 B 4.92 H
F
F H N F N N )'N 117 0 1502.92 502.82, A 8.42 F N. N N 504.80 F
H
WO 2012/078867 PCT/US2011/063943 - 80 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention M ime (min) H C N NH' F 'NH 118 0 501.38 501/503 B 4.63 N N CI H CN NH N ~ N H 119 0 516.95 517/519 B 4.42 C-" H FF H 120 N NHC 502.92 528', A 7.95 H FF ~ ~NH HN N 0 HN\\': T) 121N N 488.55 488.95 A 6.56 F H F F
F
WO 2012/078867 PCT/US2011/063943 - 81 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention 'lM e (min) H SN N 122 0 HN""(: N I 5 454.90, A 5.75 N l N>oKh 456.90 c I H CC I NH I 123 N N F 457.85 459.89 A 10.07 F H F F F HN N 124 N CI 502.92 502.89, A 8.35,8.46 NH 504.89 F ~ N N F I~ H F 0 O NH 125 CI 496.91 496.88 A 10.12 SNH 498.90 0 F N N F FI
H
WO 2012/078867 PCT/US2011/063943 - 82 Compund IW NS (E+) HI-CHPLC Compound Chemical Structure MW MS (E tho Retention T ime (min) 0 b NH 126C 496.91 496.88, A 10.13 12o HJ 498.90 F - N N F I H ctOH F (:NH F 127 0 457.9 457.87, A 9.45 N :rLN cl459.82 - N N CI F H
F'
F OH 128 O N F 425.86, A 9.43 12 NH 425.8 427.83 N N CI H F 0OH KANH F 129 0 425.8 425.88, A 8.92 FN N CI 427.83 H F F F1C9B o KLNN F 130 0L 520.9 509, B 10.35 F N Nc1542.85 F
-
NC
NH
WO 2012/078867 PCT/US2011/063943 - 83 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure M1lW MS (EI+) HPLC Retention No. (g/mol) m/z Method 'ime (min) H N Y Na . 131 O NH 512.9 512.94, A 7.78 N N CI514.93 132 0 526 A 5.98 N CI7.93 N N a C 129 I H F H N 132 0 526 525.94, A 8.92 N N F 497.89 H F H 133 0 517 516.90, A 8.42 F I518.894 ~N N N CI F H N N C I 135 0 N H j 9 9 495.92, A82 F 497.89 F
H
WO 2012/078867 PCT/US2011/063943 - 84 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure M1lW MS (EI+) HPLC Retention No. (g/mol) m/z Method 'ime (min) O H N yN, CI 136 0 NH 538 537.92, A 8.15 137N N N N2 539.88 F H N F H F HH N N NN 0 HNh1C"" Nr 138 F H N 444.5 445.03 A 5.61 H F H s N CI 139 O 0 NH 535 534.85, A 9.68 N N536.82 F H HH CI 140 0 0 N H 529 528.94, A 9.73 SN F530.84 F
H
WO 2012/078867 PCT/US2011/063943 - 85 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention Time (min) H N 141 H N 476.6 477.02 A 7.19 FH H N 142 0 HN 0 470.6 471.03 A 7.25 F ~ N IlN F ) N4' H N O O O N H 145 s ~N N 510 7.4 B 46 H F C H 14 F N 461 461.01, A 6.13 14 N I'lN - 462.96 H 0 0HNa 0 145 "'5"1 C 571.04 571.04 B 4.62 Fe I F WO 2012/078867 PCT/US2011/063943 - 86 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention Time (min) F H 8NN O 5 146 CI NH 557.01 557 B 5.08 H F H NN N 147 0 469 .02, A 7.76 Cq NH 463F.0 H F H F HH
F
WO 2012/078867 PCT/US2011/063943 - 87 Compund IW NS (E+) HI-CHPLC Compound Chemical Structure MW MS (E tho Retention T ime (min) H 151 N O 494.96 93.01, A 7.26 1N 492.97 NF H NN2 N 152 NH 490.96 491.04, A71 Cliq H" N1 - 493.01 A 71 F OH N -47N 153 476.9N53 477.00, A 6.76 0 1 F 525.03, 15 l, N N 1-, 490.96 410, A 7.38 155 ' H 493
F
WO 2012/078867 PCT/US2011/063943 - 88 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention M ime (min) IO o H 156 ci N 476.93 477.02, A 7 Cq NH N 0 1479 0 H F O H N. N 157 Ci N N 523 523.06, A 7.42 N 525.03 F H F H N~. N 159 ci NNH 474.96 473.24, A 7.5 H 475.21 F F O H 160 Ci NH N 492.95 493.24 A 8.64
F
WO 2012/078867 PCT/US2011/063943 - 89 Compund IW NS (E+) HI-C HPLC Compound Chemical Structure MW MS (Etho Retention Time (min) 161 CI N N N0 O 492.95 493.1' A 8.18 H N N 140592.7.4 528 D 2.28 161 0 49.9 49116 A 8.18 SN N 49 o H F 00 H 162 52.17 593 D 2.33 HH N N'O N Hl& NH 163 0F WO 2012/078867 PCT/US2011/063943 - 90 Compund IW NS (E+) HI-CHPLC Compound Chemical Structure MW MS (E tho Retention T ime (min) ci H N-.. N 166 ci NH 481.35 481 D 2.14 N O 0l' H F F F O H 167 F N N N O 524.96 526.86' A 10.93 o H CI H 0 CI 168 NH535.97 535.96, A 9.83 N N F537.98 F H 0 CI 169 NH529.94 530.04, A 7.14 6 FN NF 532.04 1 N H H 170 0 0 N H 53.7 535.96, A 9.22 F N W'& F537.93 F
H
WO 2012/078867 PCT/US2011/063943 - 91 Compound Chemical Structure (EI+) HPC ton No. CeiclSrcue(g/l11l) ni1/Z Method Rie (nun 'Hime (minh) QH 0 a CI 171 0 N H 529.94 529.98, A 9.72 N N F 5531.99 F H Cl 0 172 N N6 F 455.83 455.', A 10.29 FH 457.9 F F NA indicates that no data was available. * Indicates that mass spectrometry data was collected in the negative ion mode. 5 TABLE 4 CoNpound nt 'H NMR Resonance Data (S) D- 6 11.96 (s, 1H1), 8.29 (dd, 2H), 7.80 (dd, 2H), 7.47 (m, 1H1), 7.29 (m, 1 DMSO 2H), 7.17 (m, 1H1), 6.32 (d, 1H1), 4.52 (m, 1H1), 4.1 (m, 1H1), 1.8 (br mn, 4H), 1.3 (br mn, 13H). 3 CD 3 0D 7.85 (br m, 3H), 7.6 (br m, 2H), 7.5 (br i, 1H), 7.2 (br i, 1H), 3.73 (br in, 1H), 2.96 (br s, 3H), 2.1 (br mn, 4H), 1.5 (br mn, 4H). 7.97 (br in, 1), 7.82 (br mn, 2H), 7.62 (br in, 1), 7.56 (br in, 1H), 4 CD 3 0D 7.47 (br in, 1), 7.2 (br in, 1), 3.75 (br in, 1), 3.64 (br in, 1H), 2.14 (br mn, 2H), 2.00 (br mn, 2H), 1.47 (br mn, 4H). 7.84 (br mn, 3H), 7.62 (br in, 1), 7.35 (br mn, 2H), 7.22 (br mn, 2H), 5 CD 3 0D 3.75 (br in, 1), 3.63 (br in, 1), 2.12 (br mn, 2H), 2.00 (br mn, 2H), 1.45 (br mn, 4H). 7.86 (br mn, 2H), 7.5 (br in, 1H), 7.24 (br mn, 2H), 7.01 (br in, 1H), 6 CD 3 0D 3.75 (br in, 1H), 3.63 (br in, 1H), 2.12 (br mn, 2H), 2.00 (br mn, 2H), 1.45 (br mn, 4H). 10.61 (br s, 1H), 9.02 (br s, 1H), 8.12 (br mn, 2H), 7.75 (br mn, 2H), 7 CD 3 0D 7.6-7.4 (m, 2H), 7.18 (m, IH), 4.60 (m, IH), 3.77 (br m, 1H), 3.45 (b mi, 1), 1.96 (br mn, 2H), 1.84 (br mn, 2H), 1.33 (br mn, 4H).
WO 2012/078867 PCT/US2011/063943 - 92 Compound NMR 'H NMR Resonance Data (8) No. Solvent 8.18 (br m, 2H), 7.66 (br m, 3H), 7.36 (br m, 2H), 7.21 (br m, iH), 8 CD 3 0D 3.75 (br m, iH), 3.63 (br m, iH), 2.13 (br m, 2H), 2.00 (br m, 2H), 1.46 (br m, 4H). D- 6_10.55 (br s, iH), 9.1 (br s, iH), 8.25 (br m, 2H), 7.82 (br m, 2H), 7.5 9 DMSO (br m, 3H), 7.2 (br m, 2H), 6.52 (m, 1H), 3.8 (br m, 2H), 2.1 (br m, 2H), 2.0 (br m, 2H), 1.44 (br m, 4H). D- 6 10.49 (br s, iH), 9.03 (br s, iH), 7.79 (br m, 2H), 7.53-7.42 (m, 3H), 10 DMSO 7.18 (m, 2H), 3.95 (m, 2H), 3.71 (br m, iH), 1.99 (br m, 2H), 1.81 (b m, 2H), 1.33 (br m, 4H), 1.13 (m, 3H). D- 6 10.47 (br s, iH), 9.02 (br s, iH), 7.79 (br m, 2H), 7.5 (br m, 3H), 7.18 11 DMSO (br m, 2H), 3.69 (br m, IH), 3.50 (s, 3H), 1.99 (br m, 2H), 1.81 (br m, 2H), 1.35 (br m, 4H). 10.49 (br s, iH), 9.09 (br s, iH), 7.98 (br m, iH), 7.75 (br m, 3H), 7.6 14 D - (t, iH), 7.49 (d, iH), 7.39 (m, iH), 7.11 (br m, iH), 3.95 (m, 2H), DMSO 3.74 (br m, iH), 2.02 (br m, 2H), 1.96 (br m, 2H), 1.35 (br m, 4H), 1.14 (t, 3H). D- 6 10.48 (br s, iH), 9.1 (br s, iH), 7.98 (br m, iH), 7.75 (br m, 3H), 7.6 15 DMSO (t, IH), 7.49 (d, IH), 7.41 (m, IH), 7.14 (br m, IH), 3.74 (br m, IH), 3.5 (br s, 3H), 2.02 (br m, 2H), 1.83 (br m, 2H), 1.35 (br m, 4H). 10.19 (br d, IH), 7.8 (br m, IH), 7.72 (d, IH), 7.65 (br m, 3H), 7.45 16 D - (br m, 2H), 7.33 (br m, IH), 4.77 (br m, 2H), 4.60 (br m, IH), 3.58 DMSO (br m, iH), 3.45 (br m, iH), 2.0 (br m, 2H), 1.83 (br m, 2H), 1.3 (br m, 4H). D- 6_10.28 (br d, iH), 8.0 (br m, 2H), 7.8-7.6 (br m, 5H), 7.45 (br m, 2H), 17 DMSO 4.82 (br m, 2H), 4.59 (br m, iH), 3.58 (br m, iH), 3.46 (br m, iH), 2.0 (br m, 2H), 1.83 (br m, 2H), 1.31 (br m, 4H). 10.51 (br s, iH), 8.98 (br s, iH), 8.10 (br m, 2H), 7.73 (m, 2H), 7.65 18 D - (br m, iH), 7.46 (br m, iH), 7.37 (t, iH), 7.2 (m, iH), 7.12 (br m, DMSO iH), 3.96 (m, 3H), 3.73 (br m, iH), 2.01 (br m, 2H), 1.96 (br m, 2H), 1.36 (br m, 4H), 1.14 (m, 3H). D- 6 10.43 (br s, iH), 8.98 (br s, iH), 7.8 (br m, 2H), 7.65 (br m, iH), 7.4 19 DMSO (br m, 3H), 7.21 (m, iH), 7.12 (br m, iH), 3.96 (m, 3H), 3.71 (br m, iH), 2.01 (br m, 2H), 1.82 (br m, 2H), 1.34 (br m, 4H), 1.15 (m, 3H). 10.45 (br s, iH), 9.01 (br s, iH), 8.23 (br m, 2H), 7.8 (br m, 2H), 7.66 20 D - (br m, iH), 7.4 (br m, 3H), 7.21 (m, iH), 7.14 (br m, iH), 6.51 (m, DMSO iH), 3.73 (br m, 2H), 2.06 (br m, 2H), 1.96 (br m, 2H), 1.42 (br m, 4H). 10.59 (br s, iH), 9.06 (br s, iH), 8.02 (br m, iH), 7.88 (br m, 2H), 6 24 D - 7.60 (br m, 1H), 7.58 (t, IH), 7.49 (m, 2H), 7.38 (m, IH), 4.61 (d, DMSO iH), 3.78 (br m, iH), 3.46 (br m, iH), 2.0 (br m, 2H), 1.83 (br m, 2H), 1.32 (br m, 4H). D- 6_10.52 (br s, IH), 8.94 (br s, IH), 7.9 (br m, 2H), 7.72 (br m, 1H), 7.5 25 DMSO (m, iH), 7.4 (m, 3H), 7.20 (m, iH), 4.59 (br m, 1H), 3.76 (br m, 1H), 3.45 (br m, 1H), 1.97 (br m, 2H), 1.83 (br m, 2H), 1.33 (br m, 4H). D- 6 10.56 (br s, IH), 9.00 (br s, IH), 7.9 (br m, 2H), 7.6-7.4 (br m, 4H), 26 DMSO 7.18 (m, iH), 4.61 (d, iH), 3.76 (br m, 1H), 3.45 (br m, 1H), 1.96 (br m, 2H), 1.83 (br m, 2H), 1.32 (br m, 4H).
WO 2012/078867 PCT/US2011/063943 - 93 Compound NMR 'H NMR Resonance Data (8) No. Solvent D- 6 10.61 (br s, iH), 8.95 (br s, iH), 7.94 (br m, 2H), 7.6-7.4 (br m, 4H), 27 DMSO 7.16 (m, iH), 4.59 (br m, iH), 3.77 (br m, iH), 3.45 (br m, iH), 1.96 (br m, 2H), 1.82 (br m, 2H), 1.15 (br m, 4H). D - 10.56 (br s, iH), 8.88 (br s, iH), 7.93 (br m, 2H), 7.65 (br m, iH), 7.4 28 DMSO (br m, 4H), 7.18 (m, 1H), 4.60 (d, 1H), 3.75 (br m, 1H), 3.44 (br m, iH), 1.97 (br m, 2H), 1.83 (br m, 2H), 1.32 (br m, 4H). 10.60 (br s, iH), 9.03 (br s, iH), 8.05-7.9 (br m, 3H), 7.74 (br m, 6 29 D- iH), 7.58 (t, iH), 7.46 (m, iH), 7.39 (m, 2H), 4.61 (d, iH), 3.78 (br DMSO m, iH), 3.46 (br m, iH), 1.98 (br m, 2H), 1.83 (br m, 2H), 1.33 (br m, 4H). 10.58 (br s, iH), 9.09 (br s, iH), 8.18 (br m, 2H), 7.97 (br m, iH), 6 30 D - 7.8-7.7 (br m, 2H), 7.6 (m, 2H), 7.48 (m, iH), 4.59 (br m, iH), 3.79 DMSO (br m, iH), 3.47 (br m, iH), 2.01 (br m, 2H), 1.84 (br m, 2H), 1.33 (br m, 4H). 11.52 (br s, iH), 10.28 (br s, iH), 8.18 (br m, iH), 7.9-7.7 (br m, 6 69 D - 4H), 7.51 (br m, iH), 7.38 (br m, iH), 7.24 (br m, 1H), 3.75 (br m, DMSO iH), 3.44 (br m, iH), 2.05 (br m, 2H), 1.86 (br m, 2H), 1.5-1.2 (br m, 4H). D - 11.20 - 8.40 (bm, 2H), 7.93 (t, iH, J=9.2 Hz), 7.82 (s, iH), 7.54 (bs, 70 DMSO IH), 7.06 (bd, IH), 4.20 - 3.50 (m, 5H), 2.00 - 1.20 (m, 16H), 1.12 (t, 3H, J=7.2 Hz). D6- 10.95 (bs, iH), 9.40 (bs, iH), 8.80 (bs, iH), 7.95 (t, 1H, J=9.2 Hz), 76 DMSO 7.79 (bs, iH), 7.67 (bs, iH), 7.15 - 7.00 (bd, iH), 3.93 (m, 2H), 1.96 - 1. 11 (m, 18H). D - 10.50 - 10.05 (bd, iH), 7.86 (m, 2H), 7.43 (dd, iH, J=8.4 Hz, 2.0 77 DMSO Hz), 7.12 - 6.95 (m, iH), 6.67 (bs, iH), 4.01- 3.91 (m, 4H), 3.22 (bs, 1H), 1.97 - 0.86 (m, 25H). D - 10.43 (br s, iH), 8.98 (br s, iH), 7.77 (br m, 2H), 7.65 (br m, iH), 7.4 78 DMSO (br m, 3H), 7.21 (br m, iH), 6.84 (br m, iH), 3.70 (br m, iH), 3.26 (br m, iH), 1.97 (br m, 2H), 1.79 (br m, 2H), 1.36 (br m, 13H). D - 10.41 (br s, iH), 8.98 (br s, iH), 7.74 (br m, 3H), 7.41 (br m, 3H), 81 DMSO 7.12 (br m, iH), 3.94 (q, 2H), 3.7 (br m, iH), 2.00 (br m, 2H), 1.82 (br m, 2H), 1.35 (br m, 4H), 1.13 (t, 3H). D - 10.43 (br s, iH), 9.02 (br s, iH), 8.23 (br m, 2H), 7.75 (br m, 3H), 83 DMSO 7.42 (br m, 3H), 7.15 (br m, iH), 6.51 (m, iH), 3.72 (br m, 2H), 2.06 (br m, 2H), 1.94 (br m, 2H), 1.4 (br m, 4H). D - 10.80 (br s, IH), 9.00 (br s, IH), 7.83 (br m, 2H), 7.6-7.43 (br m, 85 DMSO 3H), 7.3-7.16 (br m, 2H), 4.01-3.93 (br m, 3H), 3.50 (br m, iH), 1.96-1.53 (br m, 8H), 1.14 (m, 3H). 10.52 - 10.08 (bd, iH), 8.23 (d, 2H, J=4.8 Hz), 7.94 - 7.84 (m, 2H), 6 86 D - 7.46 - 7.39 (m, iH), 7.12 - 6.98 (bd, iH), 6.72 (bs, iH), 6.50 (t, DMSO J=4.8 Hz), 4.03 - 3.87 (m, 2H), 3.67 - 3.40 (m, 2H), 1.93 (bs, 6H), 1.66 - 0.88 (m, 18H). 10.21 - 10.08 (bd, iH), 8.23 (d, 2H, J=3.2 Hz). 7.92 - 7.86 (m, 2H), 6 87 D - 7.42 (q, iH, J=8.8 Hz), 7.13 - 6.98 (bd, iH), 6.73 (bs, iH), 6.50, DMSO J=3.2 Hz), 4.03 - 3.96 (m, iH), 3.67 - 3.57 (m, 2H), 1.96 - 1.15 (m, 18H).
WO 2012/078867 PCT/US2011/063943 - 94 Compound NMR 'H NMR Resonance Data (8) No. Solvent 12.40 - 12.00 (bs, iH), 11.00 - 10.70 (bs, iH), 9.20 - 8.90 (bs, 1H), 89 D- 7.87 - 7.82 (m, 2H), 7.54 - 7.43 (m, 3H), 7.18 (d, iH, J=8.8 Hz), DMSO 4.03 - 3.98 (m, 2H), 3.04 (m, iH), 2.51 - 2.43 (m, 4H), 1.73 - 1.63 (m, 8H). D- 6 10.42 - 10.13 (m, 1H), 8.23 (d, 2H, J=4.8 Hz), 7.93 - 7.75 (m, 2H), 90 DMSO 7.45 - 7.10 (m, 5H), 6.51 (d, IH, J=4.8 Hz), 4.67 - 4.55 (m, 2H), 3.75 - 3.50 (bd, 2H), 2.06 - 1.93 (m, 6H), 1.46 - 1.35 (m, 4H). 10.17 (d, IH, J=7.6 Hz), 8.24 (d, J=4.8 Hz), 7.84 (bs, IH), 7.74 6 92 D - 7.63 (m, 4H), 7.49 - 7.41 (m, 2H), 7.32 (q, IH, J=9.6 Hz), 7.12 (d, DMSO iH, J=8.0 Hz), 6.51 (t, IH, J=4.8 Hz), 4.78 (bs, 2H), 3.73 (bs, iH), 3.58 (bs, iH), 2.09 - 1.95 (m, 4H), 1.44 - 1.35 (m, 4H). 10.12 (d, IH, J=6.4 Hz), 8.23 (d, 2H, J=4.8 Hz), 7.84 - 7.81 (m, 2H), 6 93 D - 7.72 (s, iH), 7.65 - 7.57 (m, 2H), 7.36 (q, IH, J=8.4 Hz), 7.11 (bs, DMSO iH), 6.51 (t, iH, J=4.8 Hz), 4.65 (bs, 2H), 3.69 (bs, iH), 3.50 (bs, iH), 2.00 - 1.92 (m, 4H), 1.45 - 1.32 (m, 4H). 10.51 (bs, iH), 9.13 (bs, iH), 8.24 (d, 2H, J=5.2 Hz), 7.99 (bs, iH), 6 94 D - 7.78 - 7.70 (m, 3H), 7.59 (t, iH, J=8.0 Hz), 7.48 (d, IH, J=8.0 Hz), DMSO 7.40 (q, IH, J=9.6 Hz), 7.14 (bs, iH), 6.51 (t, IH, J=5.2 Hz), 3.79 (bs, 2H), 2.06 (bs, 2H), 1.96 (bs, 2H), 1.43 (sextet, 5H, J=10.0 Hz). 12.0 (br s, iH), 8.05-7.9 (m, 2H), 7.4-7.0 (m, 6H), 4.7 (br s, iH), 4.39 97 CDC1 3 (d, iH), 4.05 (br s, iH), 3.35 (br s, iH), 3.0 (s, 3H), 2.2 (m, 4H), 1.6 1.2 (m, 5H). D- 6 10.48 (br s, iH), 9.01 (br s, iH), 7.8 (br m, 3H), 7.45 (br m, 3H), 7.18 100 DMSO (m, iH), 3.72 (br m, iH), 3.51 (br m, iH), 1.98 (br m, 2H), 1.87-1.77 (br m, 5H), 1.30 (br m, 4H). D- 6 10.49 (br s, iH), 9.03 (br s, iH), 7.97 (d, iH), 7.79 (br m, 2H), 7.46 101 DMSO (br m, 3H), 7.19 (m, iH), 3.75 (br m, iH), 3.55 (br m, iH), 2.0 (br m, 2H), 1.83 (br m, 2H), 1.48 (m, iH), 1.34 (br m, 4H), 0.62 (br m, 4H). D- 6 10.44 (br s, iH), 9.05 (br s, iH), 7.8 (br m, 2H), 7.46 (br m, 3H), 7.2 102 DMSO (m, 2H), 3.75 (br m, iH), 3.55 (br m, iH), 2.02 (br m, 2H), 1.74 (br m, 2H), 1.42 (br m, 4H), 1.06 (s, 9H). 10.5 (br s, iH), 8.0-7.8 (m, 3H), 7.1 (dd, 2H), 4.6 (br s, iH), 4.1 (m, 103 CDC1 3 2H), 3.5 (br s, iH), 2.2-2.0 (m, 2H), 1.5 (s, 9H), 1.4-1.2 (m, 6H), 1.2 (t, 3H). 11.9 (br s, iH), 8.0-7.8 (m, 2H), 7.2-7.1 (m, iH), 4.55 (br s, iH), 4.1 105 CDC1 3 (q, 2H), 3.5 (br s, iH), 2.2-2.0 (m, 4H), 1.7 (br s, 6H), 1.5-1.25 (m, 4H), 1.25 (t, 3H). 10.4 (br 2, iH), 8.0-7.8 (2H, m), 7.2-7.0 (m, iH), 4.6 (br s, iH), 4.1 106 CDC1 3 (q, 2H), 3.9 (br s, iH), 3.5 (br s, iH), 2.4-2.2 (m, 2H), 2.2-2.0 (m, 6H), 2.0-1.8 (m, 2H), 1.5 (br s, 3H), 1.3 (br s, 4H), 1.1 (t, 3H). 10.35 (br s, iH), 8.0-7.8 (m, 2H), 7.2-7.1 (m, iH), 4.6 (br s, iH), 4.35 109 CDC1 3 (br s, iH), 4.1 (q, 2H), 3.75 (br s, iH), 3.5 (br s, iH), 2.2-1.9 (m, 6H), 1.75 (br s, 2H), 1.7-1.5 (m, 4H), 1.35 (br s, 4H), 1.25 (t, 2H). 10.55 (br s, iH), 8.25 (d, 2H), 7.6 (d, 2H), 7.6 (br s, iH), 4.3 (br s, III CDC1 3 iH), 4.2-4.0 (m, 2H), 3.5 (br s, iH), 2.2-2.0 (m, 4H), 1.45 (br s, 9H), 1.4-1.3 (m, 4H), 1.3 (t, 3H). D6- 10.87 (br s, iH), 9.04 (br s, iH), 8.24 (d, 2H), 7.84 (br m, 2H), 7.58 120 DMSO (m, iH), 7.46 (m, 2H), 7.25-7.17 (m, 2H), 6.52 (t, iH), 4.0 (br m, 1H), 3.87 (br m, iH), 1.97-1.6 (m, 8H).
WO 2012/078867 PCT/US2011/063943 - 95 Compound NMR 'H NMR Resonance Data (8) No. Solvent D- 6 10.83 (d, iH), 9.01 (br s, iH), 8.14 (d, 2H), 7.76 (m, 2H), 7.57 (s, 123 DMSO IH), 7.47 (m, IH), 7.15 (m, IH), 5.14 (br m, IH), 3.91 (br m, 1H), 3.83 (br m, iH), 1.66-1.35 (m, 8H). D- 6 10.74 (d, iH), 9.00 (br s, iH), 7.84 (m, 2H), 7.54-7.41 (m, 3H), 7.16 128 DMSO (m, 1H), 5.15 (br m, 1H), 3.89 (m, 1H), 3.81 (m, 1H), 1.65-1.47 (m, 6H), 1.34 (m, 2H). D- 6 10.38 (bs, iH), 9.30 (d, iH), 7.80 (m, 2H), 7.52-7.25 (m, 3H), 7.20 130 DMSO (d, iH), 6.50 (bs, 2H), 3.80-3.60 (bd, 2H), 3.15 (s, iH), 2.05 (bs, 2H), 1.82 (m, 2H), 1.45 (m, 4H). D- 6 10.46 (br s, iH), 9.01 (br s, iH), 8.25 (m, iH), 7.8 (br m, 3H), 7.66 134 DMSO (br m, iH), 7.51-7.37 (m, 6H), 7.21 (m, 2H), 3.78 (m, 2H), 2.08 (br m, 2H), 1.91 (m, 2H), 1.5 (m, 4H). D- 6 10.50 (br s, iH), 9.06 (br s, iH), 8.26 (m, iH), 7.8-7.7 (m, 3H), 7.53 139 DMSO 7.43 (m, 2H), 7.20 (m, iH), 7.12 (m, iH), 3.75 (br m, 2H), 2.06 (br m, 2H), 1.89 (br m, 2H), 1.5 (br m, 4H). D- 6 10.51 (br s, iH), 9.07 (br s, IH), 8.25 (m, iH), 7.81 (br m, 3H), 7.53 140 DMSO 7.42 (m, 5H), 7.20 (m, iH), 3.8 (br m, 2H), 2.06 (br m, 2H), 1.47 (br m, 4H). D- 6 10.65 (br s, iH), 8.87 (br s, iH), 7.86 (m, 2H), 7.58 (m, iH), 7.48 (m, 147 DMSO iH), 7.18 (m, 4H), 3.72 (br m, iH), 3.49 (s, 3H), 2.31 (s, 3H), 1.96 (m, 2H), 1.82 (m, 2H), 1.34 (br m, 4H). D- 6 10.69 (br s, iH), 8.93 (br s, iH), 8.26 (m, iH), 7.88 (m, 2H), 7.81 (m, 148 DMSO 2H), 7.61 (m, iH), 7.51-7.42 (m, 4H), 7.19 (m, 3H), 3.78 (m, 2H), 2.31 (s, 3H), 2.06 (m, 2H), 1.94 (m, 2H), 1.56-1.40 (m, 4H). D- 6 10.66 (br s, iH), 8.92 (br s, iH), 7.97 (m, 2H), 7.6-7.36 (m, 5H), 7.15 149 DMSO (m, 2H), 3.95 (q, 2H), 3.74 (m, iH), 1.99 (m, 2H), 1.82 (m, 2H), 1.33 (m, 4H), 1.13 (t, 3H). D- 6 10.65 (br s, iH), 8.91 (br s, iH), 7.97 (m, 2H), 7.6-7.36 (m, 5H), 7.15 150 DMSO (m, 2H), 3.73 (m, iH), 3.58 (s, 3H), 1.97 (m, 2H), 1.81 (m, 2H), 1.34 (m, 4H). D- 6 10.69 (br s, iH), 8.97 (br s, iH), 8.26 (m, iH), 7.99 (m, 2H), 7.81 (m, 151 DMSO 2H), 7.6-7.37 (m, 8H), 7.17 (m, iH), 3.79 (br m, 2H), 2.07 (m, 2H), 1.90 (m, 2H), 1.47 (m, 4H). D- 6 10.66 (br s, iH), 8.86 (br s, iH), 7.92 (m, 2H), 7.6-7.4 (m, 2H), 7.14 152 DMSO (m, 2H), 6.91 (m, 2H), 3.94 (m, 2H), 3.77 (s, 3H), 3.72 (m, iH), 1.97 (m, 2H), 1.81 (m, 2H), 1.33 (m, 4H), 1.15 (m, 3H). D- 6 10.67 (br s, IH), 8.85 (br s, IH), 7.92 (m, iH), 7.67-7.4 (m, 2H), 7.14 153 DMSO (m, 2H), 6.91 (m, 2H), 3.8-3.65 (m, 4H), 3.49 (s, 3H), 1.97 (m, 2H), 1.82 (m, 2H), 1.33 (br m, 4H). D- 6 10.70 (br s, iH), 8.89 (br s, iH), 8.26 (m, iH), 7.94 (m, 2H), 7.81 (m, 154 DMSO 2H), 7.6-7.42 (m, 5H), 7.15 (m, iH), 6.92 (m, 2H), 3.77 (br m, 5H), 2.06 (m, 2H), 1.90 (m, 2H), 1.55-1.37 (m, 4H). D- 6 10.68 (br s, IH), 8.92 (br s, IH), 7.54 (m, 5H), 7.55 (m, iH), 7.16 (m, 155 DMSO iH), 7.02 (m, iH), 3.95 (m, 2H), 3.73 (m, 4H), 1.97 (m, 2H), 1.82 (m, 2H), 1.34 (m, 4H), 1.13 (m, 3H). D- 6 10.67 (br s, IH), 8.92 (br s, IH), 7.54 (m, 5H), 7.29 (m, iH), 7.16 (m, 156 DMSO iH), 7.01 (m, iH), 3.73 (m, 4H), 3.49 (s, 3H), 1.96 (m, 2H), 1.96 (m, 2H), 1.35 (m, 4H).
WO 2012/078867 PCT/US2011/063943 - 96 Compound NMR 'H NMR Resonance Data (8) No. Solvenit D- 6 10.70 (br s, 1H), 8.96 (br s, 1H), 8.27 (m, 1H), 7.81 (m, 2H), 7.6-7.4 157 DMSO (m, 5H), 7.3 (m, 1H), 7.17 (m, 1H), 7.02 (m, 1H), 3.8-3.65 (m, 5H), 2.07 (m, 2H), 1.93 (m, 2H), 1.47 (m, 4H). D- 6 10.67 (br s, 1H), 8.88 (br s, 1H), 7.87 (m, 2H), 7.6-7.48 (m, 2H), 7.18 158 DMSO (m, 4H), 3.96 (m, 2H), 3.73 (m, 1H), 2.31 (s, 3H), 1.97 (m, 2H), 1.82 (m, 2H), 1.33 (m, 2H), 1.13 (m, 3H). D- 6 10.65 (br s, 1H), 8.90 (br s, 1H), 7.83-7.68 (m, 3H), 7.47 (m, 1H), 159 DMSO 7.26 (m, 2H), 7.15 (m, 2H), 3.96 (m, 2H), 3.73 (m, 1H), 2.30 (s, 3H), 1.97 (m, 2H), 1.82 (m, 2H), 1.34 (m, 2H), 1.13 (m, 3H). D- 6 10.55 (br s, 1H), 8.95 (br s, 1H), 7.68 (m, 1H), 7.60 (m, 2H), 7.44 (m, 160 DMSO 1H), 7.29 (m, 1H), 7.17-7.05 (m, 2H), 3.95 (m, 2H), 3.74 (m, 1H), 2.24 (s, 3H), 1.97 (m, 2H), 1.82 (m, 2H), 1.33 (m, 4H), 1.14 (m, 3H). D- 6 10.58 (br s, 1H), 8.93 (br s, 1H), 7.90 (m, 1H), 7.80 (m, 1H), 7.64 (m, 161 DMSO 1H), 7.43 (m, 1H), 7.14 (m, 3H), 3.96 (m, 2H), 3.72 (m, 1H), 2.22 (s, 3H), 1.97 (m, 2H), 1.82 (m, 2H), 1.33 (m, 4H), 1.13 (m, 3H). D- 6 10.48 (br s, 1H), 9.03 (br s, 1H), 7.79 (m, 2H), 7.53-7.42 (m, 3H), 167 DMSO 7.18 (m, 1H), 6.83 (m, 1H), 3.71 (m, 1H), 1.96 (m, 2H), 1.79 (m, 2H), 1.36 (m, 13H). D- 6 10.48 (br s, 1H), 9.11 (br s, 1H), 8.82 (br s, 1H), 7.98 (m, 2H), 7.80 168 DMSO (m, 2H), 7.53-7.42 (m, 3H), 7.19 (m, 1H), 3.78 (m, 2H), 2.0 (m, 2H), 1.84 (m, 2H), 1.64 (m, 2H), 1.43 (m, 2H). D- 6 10.50 (br s, 1H), 9.06 (br s, 1H), 8.96 (m, 1H), 8.68 (m, 1H), 8.45 (m, 169 DMSO 1H), 8.14 (m, 1H), 7.81 (m, 2H), 7.4 (m, 4H), 7.19 (m, 1H), 3.80 (m, 2H), 2.06 (m, 2H), 1.92 (m, 2H), 1.45 (m, 4H). D - 6_ 10.49 (br s, 1H), 9.15 (s, 1H), 9.11 (br s, 1H), 8.35 (br s, 1H), 8.28 (s, 170 DMSO 1H), 7.80 (m, 2H), 7.49-7.42 (m, 3H), 7.18 (m, 1H), 3.79 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.58 (m, 2H), 1.44 (m, 2H). D- 6 10.50 (br s, 1H), 9.12 (br s, 1H), 8.62 (m, 2H), 7.95 (m, 2H), 7.81 (m, 171 DMSO 2H), 7.57-7.35 (m, 4H), 7.18 (m, 1H), 3.82 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.60 (m, 2H), 1.45 (m, 2H). EXAMPLE 5 [0179] Compounds in Example 4 above were tested for activity against FiFo-ATPase by 5 measuring ATP synthesis. In addition, the compounds were assessed for cytotoxicity in Ramos cells. Results of the biological activity tests are shown in Table 5 below. Inhibition of ATP synthesis by the FiFo-ATPase and cytotoxicity in Ramos cells were measured according to the procedures described in K. M. Johnson et al. Chemistry & Biology 2005, 12, 485-496. NA indicates that no data was available.
WO 2012/078867 PCT/US2011/063943 - 97 TABLE 5 Compound ATP Synthesis Ramos cell TPSA No. IC1o (F) EC< (7 .) 2 <10 <10 73.72 2 <10 <10 73.72 3 <10 <10 99.70 4 <10 <10 73.72 5 >10 <10 73.72 6 <10 <10 73.72 7 <10 <10 73.72 8 <10 <10 73.72 9 <10 <10 90.24 10 <10 <10 91.82 11 <10 <10 91.82 12 >10 <10 79.51 13 >10 <10 79.51 14 <10 <10 91.82 15 <10 <10 91.82 16 >10 <10 73.72 17 <10 <10 73.72 18 <10 <10 91.82 19 <10 <10 91.82 20 <10 <10 90.24 21 <10 <10 73.72 22 >10 >10 73.72 23 >10 >10 73.72 24 <10 <10 73.72 25 >10 <10 73.72 26 <10 <10 73.72 27 >10 <10 73.72 28 >10 <10 73.72 29 <10 <10 73.72 30 <10 <10 73.72 31 >10 >10 73.72 WO 2012/078867 PCT/US2011/063943 - 98 Compound ATP Synthesis Ramos cell TPSA No. >0 0(F) EC77 (2 ) 32 >10 >10 73.72 33 >10 <10 73.72 34 >10 <10 73.72 35 >10 >10 73.72 36 >10 >10 73.72 37 >10 >10 73.72 38 >10 >10 73.72 39 >10 <10 73.72 40 >10 >10 73.82 41 >10 >10 73.82 42 >10 >10 73.82 43 >10 >10 73.72 44 >10 <10 73.72 45 <10 <10 73.72 46 >10 <10 73.72 47 <10 <10 91.82 48 <10 <10 91.82 49 <10 <10 91.82 50 <10 <10 91.82 51 <10 <10 91.82 52 <10 <10 91.82 53 <10 <10 91.82 54 <10 <10 91.82 55 <10 <10 91.82 56 <10 <10 91.82 57 <10 <10 91.82 58 <10 <10 91.82 59 <10 <10 91.82 60 <10 <10 91.82 61 <10 <10 91.82 62 <10 <10 91.82 63 <10 <10 91.82 66 <10 <10 91.82 WO 2012/078867 PCT/US2011/063943 - 99 Compound ATP Synthesis Ramos cell TPSA No. ic30, (FM) EC:;( (O MI) 67 <10 >10 90.24 68 <10 <10 73.72 69 <10 <10 73.72 70 >10 >10 92.00 71 <10 >10 73.72 72 <10 <10 90.24 73 <10 <10 90.24 74 <10 <10 90.24 75 <10 <10 90.24 76 <10 >10 92.00 77 <10 <10 92.00 78 <10 <10 91.80 79 >10 <10 79.51 80 >10 >10 113.00 81 <10 <10 91.82 82 <10 <10 91.82 83 <10 <10 90.24 84 <10 >10 90.24 85 <10 <10 91.82 86 <10 <10 90.00 87 <10 <10 90.00 88 <10 <10 77.88 89 <10 <10 83.00 90 <10 <10 90.00 91 <10 <10 90.00 92 <10 <10 90.00 93 <10 <10 90.00 94 <10 <10 90.00 95 <10 >10 92.00 96 <10 <10 99.70 97 >10 <10 99.70 98 <10 <10 91.82 99 >10 >10 91.00 WO 2012/078867 PCT/US2011/063943 - 100 Compound ATP Synthesis Ramos cell TPSA No. ic<0 (<1) EC85 (9 ) 100 <10 <10 82.59 101 <10 <10 82.59 102 <10 <10 82.59 103 >10 >10 91.92 104 >10 >10 91.82 105 >10 >10 91.82 106 >10 >10 91.82 107 >10 >10 91.82 108 >10 >10 73.72 109 >10 >10 91.82 110 <10 >10 91.82 111 <10 >10 91.82 112 >10 >10 90.24 113 <10 <10 90.24 114 <10 <10 90.24 115 <10 <10 90.24 116 <10 <10 90.24 117 <10 <10 90.24 118 <10 <10 90.24 119 <10 <10 90.24 120 <10 <10 90.24 121 <10 <10 90.24 122 <10 <10 90.24 123 <10 <10 73.72 124 <10 <10 90.24 125 <10 <10 91.82 126 <10 <10 91.82 127 NA <10 73.72 128 <10 <10 73.72 129 <10 <10 73.72 130 <10 <10 83.00 131 <10 <10 107.30 132 <10 <10 94.95 WO 2012/078867 PCT/US2011/063943 - 101 Compound ATP Synthesis Ramos cell TPSA No. ic<0 (<1) EC85 (9 ) 133 <10 <10 82.59 134 <10 <10 82.59 135 <10 <10 85.83 136 <10 <10 95.06 137 <10 <10 85.83 138 <10 <10 90.24 139 <10 <10 82.59 140 <10 <10 82.59 141 <10 <10 82.59 142 <10 <10 82.59 143 <10 <10 90.24 144 <10 <10 90.24 145 >10 >10 126 146 >10 >10 126 147 <10 <10 91.8 148 <10 <10 82.6 149 <10 <10 91.8 150 <10 >10 91.8 151 <10 <10 82.6 152 <10 <10 101 153 <10 <10 101 154 <10 <10 91.8 155 <10 <10 101 156 <10 <10 101 157 <10 <10 91.8 158 <10 <10 91.8 159 <10 <10 91.8 160 <10 <10 91.8 161 <10 <10 91.8 162 >10 >10 130.1 163 <10 <10 85.8 164 <10 <10 82.6 165 <10 <10 91.8 WO 2012/078867 PCT/US2011/063943 - 102 Compound ATP Synthesis Ramos cell TPSA No. ic30, (FMu) EC:;( (O MI) 166 <10 <10 91.8 167 <10 <10 91.8 168 <10 <10 95.5 169 <10 <10 95.5 170 <10 <10 95.5 171 <10 <10 95.5 172 <10 <10 70.6 INCORPORATION BY REFERENCE [0180] The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes. EQUIVALENTS [0181] The invention may be embodied in other specific forms without departing from the 5 spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein. 10 [0182] What is claimed is :

Claims (42)

1. A compound represented by Formula I:
I
including all stereoisomers, geometric isomers, and tautomers; or a pharmaceutically acceptable salt or solvate of any of the foregoing; wherein:
A is cycloalkylene;
R1 represents independently for each occurrence halogen, haloalkyl, alkyl, cycloalkyl, heterocycloalkyl, hydroxyl, Q-Cealkoxy, cyano, -C02R9, -C(0)R10, -S(0)R10, -S02R10, -S02N(Ru)(R12), -C(0)N(Ru)(R12), -N(Rn)(R12), or -N(R9)C(0)(R10);
R represents independently for each occurrence hydrogen or alkyl; R3 is -N(R5)C02R6, -N(R5)C(0)R6, -N(R5)C(0)N(R7)(R8), -N(R5)S02R6, -N(R7)(R8), -OC(0)N(R7)(R8), -OC(0)R6, -OR5, -C(0)N(R7)(R8), -C02R5, -C(0)R5, oxo, alkyl, haloalkyl, or heterocyclyl;
R4 is aryl, aralkyl, cycloalkyl, -alkylene-cycloalkyl, alkyl, or haloalkyl, wherein said aryl, aralkyl, and cycloalkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, cycloalkyl, Ci-C6alkoxy, -N(R5)C02R6, and -N(R5)C(0)R6;
R5 represents independently for each occurrence hydrogen, alkyl, cycloalkyl, haloalkyl, or heterocycloalkyl;
R6 represents independently for each occurrence alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heterocyclyl, or -alkylene-heterocyclyl;
R 7 and R 8 each represent independently for each occurrence hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkenylene, aryl, or heterocyclyl; or R 7 and R 8 are taken together with the nitrogen to which they are attached to form a 3-7 membered heterocyclic ring; R represents independently for each occurrence hydrogen, alkyl, or cycloalkyl;
R10 represents independently for each occurrence alkyl or cycloalkyl;
R 11 and R 12 each represent independently for each occurrence hydrogen, alkyl, or cycloalkyl; or R 11 and R 12 are taken together with the nitrogen atom to which they are attached to form a 3 to 7 membered heterocyclic ring optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, hydroxyl, alkyl, cycloalkyl, and Q-Cealkoxy; and
n is 0, 1, 2, or 3.
2. The compound of claim 1, wherein A is cycloalkylene, that in addition to R , is optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, alkyl, haloalkyl, cycloalkyl, -N(R5)C02R6, -N(R5)C(0)R6, -N(R7)(R8), -OR5, and -C(0)R5.
3. The compound of claim 1, wherein A is cyclobutylene, cyclopentylene, or cyclohexylene.
4. The compound of claim 1, wherein A is cyclobutylene, cyclopentylene, or cyclohexylene, each of which is, in addition to R , optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen, alkyl, haloalkyl, hydroxyl, and -N(R7)(R8).
5. The compound of claim 1, wherein A is cyclohexylene.
6. The compound of any one of claims 1-5, wherein R1 represents independently for each occurrence halogen, haloalkyl, alkyl, or Q-Cealkoxy.
7. The compound of any one of claims 1-5, wherein R1 represents independently for each occurrence chloro, fluoro, or trifluoromethyl.
8. The compound of any one of claims 1-7, wherein R is hydrogen.
9. The compound of any one of claims 1-8, wherein R3 is -N(R5)C02R6, -N(R5)C(0)R6, -N(R5)C(0)N(R7)(R8), -N(R5)S02R6, -N(R7)(R8), -OC(0)N(R7)(R8), -OC(0)R6, -OR5, -C(0)N(R7)(R8), or -C02R6.
10. The compound of any one of claims 1-8, wherein R3 is -N(R5)C02R6, -N(R5)C(0)R6, -N(R5)C(0)N(R7)(R8), -N(R5)S02R6, or -N(R7)(R8).
11. The compound of any one of claims 1-8, wherein R3 is -N(R5)C02R6.
12. The compound of any one of claims 1-8, wherein R3 is -N(R5)C(0)R6.
13. The compound of any one of claims 1-8, wherein R3 is -N(R5)C(0)N(R7)(R8) or
-N(R5)S02R6.
14. The compound of any one of claims 1-8, wherein R3 is -OC(0)N(R7)(R8), -OC(0)R6, or -OR5.
15. The compound of any one of claims 1-8, wherein R3 is -C(0)N(R7)(R8) or -C02R5.
16. The compound of any one of claims 1-8, wherein R 3 is -N(R 7 )(R 8 ).
17. The compound of any one of claims 1-16, wherein R4 is aryl or aralkyl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, cycloalkyl, and Q-Cealkoxy.
18. The compound of any one of claims 1-16, wherein R4 is phenyl optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, cycloalkyl, and Q-Cealkoxy.
19. The compound of any one of claims 1-16, wherein R4 is phenyl substituted with 1, 2, or 3 substituents independently selected from the group consisting of chloro, fluoro, trifluoromethyl, cyclopropyl, and (C1-C4)alkyl.
20. The compound of any one of claims 1-16, wherein R4 is phenyl substituted with 1 or 2 substituents independently selected from the group consisting of chloro, fluoro, and trifluoromethyl.
21. The compound of any one of claims 1-16, wherein R4 is benzyl substituted with 1, 2, or 3 substituents independently selected from the group consisting of chloro, fluoro, trifluoromethyl, cyclopropyl, and (C1-C4)alkyl.
22. The compound of any one of claims 1-15, wherein R5 represents independently for each occurrence hydrogen or (C1-C4)alkyl.
23. The compound of any one of claims 1-14, wherein R6 represents independently for each occurrence (Ci-C4)alkyl, (C3-C7)cycloalkyl, or haloalkyl.
24. The compound of any one of claims 1-14, wherein R6 is heterocyclyl.
25. The compound of any one of claims 1-14, wherein R6 is heteroaryl.
26. The compound of any one of claims 1-25, wherein R 7 and R 8 each represent
independently for each occurrence hydrogen, alkyl, cycloalkyl, or heterocyclyl.
27. The compound of any one of claims 1-25, wherein R 7 is hydrogen, and R 8 is hydrogen, methyl, ethyl, propyl, or butyl.
28. The compound of any one of claims 1-25, wherein R 7 is hydrogen, and R 8 is a 6- membered aromatic heterocyclyl.
29. The compound of any one of claims 1-28, wherein n is 1 or 2.
30. The compound of any one of claims 1-5 or 8-29, wherein n is 0.
31. The compound of claim 1, wherein said compound is represented by Formula I-Al:
(I-Al)
including all stereoisomers, geometric isomers, and tautomers; or a pharmaceutically acceptable salt or solvate of any of the foregoing; wherein:
R 1 and R 2 each represent independently hydrogen, chloro, fluoro, -CF3, methyl, or methoxyl;
R3 is -N(R5)C02R6, -N(R5)C(0)R6, -N(R5)C(0)N(R7)(R8), -N(R5)S02R6, -N(R7)(R8), -OC(0)N(R7)(R8), -OC(0)R6, -OH, -C(0)N(R7)(R8), -C02R5, haloalkyl, or heterocyclyl;
R4 is aryl, aralkyl, cycloalkyl, -alkylene-cycloalkyl, alkyl, or haloalkyl, wherein said aryl, aralkyl, and cycloalkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, alkyl, cycloalkyl, and Ci-C6alkoxy; R5 represents independently for each occurrence hydrogen, alkyl, cycloalkyl, haloalkyl, or heterocycloalkyl;
R6 represents independently for each occurrence alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heterocyclyl, or -alkylene-heterocyclyl; and
R 7 and R 8 each represent independently for each occurrence hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkenylene, aryl, or heterocyclyl; or R 7 and R 8 are taken together with the nitrogen to which they are attached to form a 3-7 membered heterocyclic ring.
32. The compound of claim 31, wherein R 1 and R 2 are chloro or fluoro.
33. The compound of claim 31 or 32, wherein R3 is -N(R5)C02R6; R5 is hydrogen or methyl; and R6 is methyl, ethyl, propyl or butyl.
34. The compound of any one of claims 31-33, wherein R4 is phenyl substituted with 1 or 2 substituents independently selected from the group consisting of chloro, fluoro, and trifluoromethyl.
35. The compound of claim 1, wherein the compound is one of compounds listed in Tables 1- 3 or a pharmaceutically acceptable salt or hydrate thereof.
36. A pharmaceutical composition comprising a compound of any one of claims 1-35 and a pharmaceutically acceptable carrier.
37. A method of treating a disorder selected from the group consisting of an immune
disorder, inflammatory disorder, cardiovascular disease, myeloma, lymphoma, cancer, and bacterial infection, comprising administering to a patient in need thereof a
therapeutically effective amount of a compound of any one of claims 1-35 in order to ameliorate a symptom of the disorder.
38. The method of claim 37, wherein the disorder is rheumatoid arthritis, psoriasis, chronic graft- versus-host disease, acute graft- versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, psoriasis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, asthma, uveitis, or epidermal hyperplasia.
39. The method of claim 37, wherein the disorder is cartilage inflammation, bone
degradation, arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reter's Syndrome, SEA Syndrome, juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, dermatomyositis, psoriatic arthritis, vasculitis, myolitis, polymyolitis, dermatomyolitis, osteoarthritis, polyarteritis nodossa, Wegener's granulomatosis, arteritis, polymyalgia rheumatica, sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, atherosclerosis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Type I diabetes mellitus, Graves' disease, Addison's disease, Raynaud's phenomenon, or autoimmune hepatitis.
40. The method of any one of claims 37-39, wherein the patient is a human.
41. A method of inhibiting a FiFo-ATPase, comprising exposing a FiFo-ATPase to a
compound of any one of claims 1-35.
42. The method of claim 41, wherein the FiFo-ATPase is mitochondrial FiFo-ATPase.
AU2011338302A 2010-12-08 2011-12-08 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof Abandoned AU2011338302A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42089910P 2010-12-08 2010-12-08
US61/420,899 2010-12-08
PCT/US2011/063943 WO2012078867A2 (en) 2010-12-08 2011-12-08 Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
AU2011338302A1 true AU2011338302A1 (en) 2013-07-11

Family

ID=46207741

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011338302A Abandoned AU2011338302A1 (en) 2010-12-08 2011-12-08 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof

Country Status (4)

Country Link
EP (1) EP2648736A4 (en)
AU (1) AU2011338302A1 (en)
CA (1) CA2820035A1 (en)
WO (1) WO2012078867A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169199B2 (en) 2010-12-08 2015-10-27 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
CA2820044A1 (en) 2010-12-08 2012-06-14 Lycera Corporation Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
SI2648511T1 (en) 2010-12-08 2017-11-30 Lycera Corporation Pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
WO2013185048A2 (en) 2012-06-08 2013-12-12 Lycera Corporation Heterocyclic guanidine f1f0-atpase inhibitors and therapeutic uses thereof
WO2013185046A1 (en) 2012-06-08 2013-12-12 Lycera Corporation Saturated acyl guanid1ne for inhibition of f1f0-atpase
WO2013185045A1 (en) 2012-06-08 2013-12-12 Lycera Corporation Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof
CA2931851A1 (en) * 2013-12-10 2015-06-18 Lycera Corporation Trifluoromethyl pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
US9914706B2 (en) 2013-12-10 2018-03-13 Lycera Corporation N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
US9815791B2 (en) 2013-12-10 2017-11-14 Lycera Corporation Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276348B2 (en) * 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
EP1450901A4 (en) * 2001-12-10 2005-05-25 Bristol Myers Squibb Co (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
AU2003276648A1 (en) * 2002-06-17 2003-12-31 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
CA2659549C (en) * 2006-06-09 2013-07-30 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
CN101855203B (en) * 2007-09-14 2014-03-19 密执安州立大学董事会 F1F0-ATPase inhibitors and related methods

Also Published As

Publication number Publication date
WO2012078867A3 (en) 2014-04-03
CA2820035A1 (en) 2012-06-14
EP2648736A2 (en) 2013-10-16
WO2012078867A2 (en) 2012-06-14
EP2648736A4 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
AU2011338302A1 (en) Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
US9169199B2 (en) Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
JP6050242B2 (en) Pyridonylguanidine F1F0-ATPase inhibitor and therapeutic use thereof
AU2009291632B2 (en) Aryl guanidine F1F0-ATPase inhibitors and related methods
DK2648511T3 (en) PYRAZOLYLGUANIDINE-F1F0 ATPASE INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF
US10085972B2 (en) Trifluoromethyl pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
EP2861225A1 (en) Saturated acyl guanid1ne for inhibition of f1f0-atpase
US9221814B2 (en) Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof
EP2866796A1 (en) Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof
US20180222867A1 (en) N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
CA2931850A1 (en) Alkylpyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted